[go: up one dir, main page]

WO1993010813A1 - Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use - Google Patents

Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use Download PDF

Info

Publication number
WO1993010813A1
WO1993010813A1 PCT/US1992/009933 US9209933W WO9310813A1 WO 1993010813 A1 WO1993010813 A1 WO 1993010813A1 US 9209933 W US9209933 W US 9209933W WO 9310813 A1 WO9310813 A1 WO 9310813A1
Authority
WO
WIPO (PCT)
Prior art keywords
pemphigus vulgaris
pva
cell
antigen
dna fragment
Prior art date
Application number
PCT/US1992/009933
Other languages
French (fr)
Inventor
John R. Stanley
Masayuki Amagai
Vera Klaus-Hovtun
Original Assignee
THE UNITED STAES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THE UNITED STAES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES filed Critical THE UNITED STAES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Publication of WO1993010813A1 publication Critical patent/WO1993010813A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the DNA sequence and clones can be used for diagrostic purposes.
  • pemphigus vulgaris antigen proteins have been made from the cDNA and these proteins have been used to raise antibodies. These proteins can also be used in ELISA assays for detection of
  • It is another object of the present invention to provide a method of detecting the presence of pemphigus vulgaris antigen in a sample comprising the steps of contacting the sample with the above-described antibody, and detecting the presence or absence of a complex formed between the pemphigus vulgaris antigen and the antibody.
  • A PV IgG affinity-purified on immunoblots of the 130-kD PVA.
  • B PV IgG affinity-purified by epitope selection on the fusion protein produced by clone MJ315.
  • C Control for B, epitope selection of PV serum by irrelevant clones.
  • D Rabbit antibodies raised against the MJ315 fusion protein.
  • Lane 4-NHEK positive control for PVA mRNA
  • Lane 5-human brain lane 6- human heart
  • lane 7-human lung lane 8-human liver
  • lane 9-human kidney lane 10-human placenta.
  • Lane 4-10 were exposed for 15 hr, and corresponding actin lanes were exposed for 2 hr. Even when exposed for 72 hr, lanes 5-10 did now show PVA mRNA) .
  • the putative signal sequence and transmembrane domain are marked by a dashed and double underline, respectively.
  • the p asumed recognition site for proteolytic cleavage is underlined.
  • the R-A-L sequence, which corresponds to the H-A-V sequence of typical cadherins is boxed.
  • Putative Ca 2+ -binding sites are shaded.
  • Horizontal arrows under the amino acid sequence show beginning of each domain.
  • the + ' s indicate the repetitive N-V/Y-X- V-T-E domains shared by PVA and DGI.
  • the identity and similarity of DGI and P-cadherin to PVA are shown for each domain to the right of the sequences. (NS indicates that similarity is not significant).
  • keratinocyte cells cause loss of cell-to-cell adhesion and blister formation.
  • the autoantibodies are specific to PVA, which has been characterized as a 130-kD glycoprotein linked by disulfide bonds to plakoglobin.
  • this invention relates to DNA sequences (including cDNA sequences) that encode PVA.
  • the invention further relates to DNA sequences that encode the entire amino acid sequence given in Figure 7 (the specific DNA sequence given in Figure 7 being only one example), or any portion comprising at least 12 base pairs thereof.
  • DNA sequences to which the invention relates also include those encoding proteins (or polypeptides) having substantially the same autoantibody binding characteristics of PVA (for example, allelic forms of the amino acid sequence of Figure 7).
  • extension clones contain one long continuous open reading frame encoding a protein of approximately the correct molecular weight and isoelectric point.
  • proteins or polypeptides having an amino acid sequence corresponding to any portion that is at least 4 amino acids of the protein depicted in Figure 7 (or allelic variations thereof).
  • the protein or polypeptides having an amino acid sequence corresponding to any portion that is at least 4 amino acids of the protein depicted in Figure 7 (or allelic variations thereof).
  • the protein or polypeptides having an amino acid sequence corresponding to any portion that is at least 4 amino acids of the protein depicted in Figure 7 (or allelic variations thereof).
  • the protein or
  • polypeptide can have an amino acid sequence corresponding to an epitope of the sequence of Figure 7 (or allelic variation thereof).
  • the protein can be used as an antigen, in protocols known in the art, to produce antibodies thereto, both monoclonal and polyclonal.
  • invention relates to a recombinant DNA molecule that includes a vector and a DNA sequence as described above (advantageously, a DNA sequence encoding the protein shown in Figure 7 or a protein having the autoantibody binding characteristics of that
  • the vector can take the form of a virus, a plasmid, or eukaryotic expression vector (for example, lambda gTII, pUEX, bacillovirus vectors and pcDNAIneo expression vectors).
  • the DNA sequence can be present in the vector operably linked to
  • the recombinant molecule can be suitable for transforming procaryotic or transfecting
  • eukaryotic cells advantageously, mammalian cells or insect cells.
  • pUEX plasmids are suitable for transforming bacterial cells
  • pcDNAIneo vector is suitable for eukaryotic
  • the present invention relates to host cells stably transformed or transfected with the above-described recombinant constructs.
  • the host cell can be prokaryotic (for example, bacterial), lower eukaryotic (for example, yeast or insect) or higher eukaryotic (for example, all mammals, including but not limited to mouse and human).
  • prokaryotic for example, bacterial
  • lower eukaryotic for example, yeast or insect
  • higher eukaryotic for example, all mammals, including but not limited to mouse and human.
  • transfections can be accomplished into Chinese hamster ovary cells (CHO) or COS-7 cells.
  • Transformation or transfection can be accomplished using protocols and materials well known in the art.
  • the transformed or transfected host cells can be used as a source of the DNA sequences described above (which sequence constitutes part of the recombinant construct).
  • the transformed or transfected cells can be used as a source for the above-described PVA protein.
  • an antibody can be raised against a peptide having the amino acid sequence of Figure 7 , or against a portion thereof of at least 4 amino acids in length.
  • Persons skilled in the art using standard methodology can raise monoclonal and polyclonal antibodies to the protein (or
  • polypeptide or a unique portion thereof.
  • the present invention relates to a method of detecting the presence of PVA or antibodies against PVA in a sample.
  • a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), all or a unique portion of the synthetic PVA protein described above, and contacting it with the serum of a person suspected of having PV.
  • the presence of a resulting complex formed between the PVA and antibodies specific therefor in the serum can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colorimetry. This method of detection can be used, for example, for the diagnosis of PV.
  • a diagnostic kit which contains recombinantly produced PVA and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence of antibodies to PVA in serum or a tissue sample.
  • Tissue samples contemplated can be monkey and human, or other mammals such as dog.
  • the present invention relates to a therapeutic method for the treatment of PV disease.
  • Plasmapheresis can be conducted on an individual having PV. Before reinfusion of the blood back into the individual, persons skilled in the art using standard
  • NHEK (Clonetics) were culture in keratinocyte grovth medium (Clonetics) nich has a Ca 2+ concentratic. of 0.15 mM. In some experiments the Ca 2+ concentration was raised to 2.55 mM for 24 hr before RNA extraction and for 48 hr before indirect immunofluorescence.
  • human foreskin epidermal cells were cultured on 3T3 cells as previously described (Rheinwald and Green, 1975; Fuchs and Green, 1981; Stanley et al., 1984), either with or without 2.5 ⁇ g/ml tunicamycin (Sigma), which was added for 1 hr before the
  • esophagus the standard substrate to detect PVA with patients' sera, or on cultured NHEK as previously described (Sabolinski et al., 1987; Stanley et al., 1981, 1982).
  • Proteins from cultured NHEK were extracted with sodium dodecyl sulfate (SDS) sample buffer with reduction, separated by SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to
  • nitrocellulose membranes (Hashimoto et al., 1990; Towbin et al., 1979). Immunoblotting was performed with human sera or rabbit antisera and alkaline phosphatase labeled goat anti-human or anti-rabbit IgG (Stanley et al., 1984; Amagai et al., 1990).
  • affinity purification of PV IgG horizontal strips of nitrocellulose containing the 130-kD PVA were cut out, incubated wtih PV serum, washed, then bound antibodies were eluted with acid glycine buffer, neutralized, dialyzed against phosphate buffered saline, and concentrated as described (Mueller et al., 1989). Construction and screening of cDNA Library
  • cDNA was synthesized with random primers and the reverse transcriptase Superscript (Gibco-BRL) by the basic method of Gubler and
  • the cDNA library was screened at high stringency by hybridization with MJ315 labeled with 32 P by random primer labeling (Maniatis et al., 1982). From approximately 10 6 recombinant clones, E12 and E33 were isolated, and plaque purified.
  • Plaque lifts of nitrocellulose-bound fusion protein produced by MJ315 in ⁇ gt11 were used to affinity purify antibodies from the PV serum as described previously (Stanley et al., 1988).
  • the MJ315 cDNA insert was excised from its pGEM plasmid vector by amplification with polymerase chain reaction (PCR) with primers that annealed to both ends and that included either a BamHI or PstI site, so that the insert could be directionally subcloned, in frame, into the BamHI-PstI site of the expression plasmid vector pUEX 1 (Amersham).
  • PCR polymerase chain reaction
  • the crude ⁇ -galactosidase fusion protein produced by pUEX was isolated as previously described for fusion proteins produced in pEX (Tanaka et al., 1990).
  • the precipitated fusion protein was then partially purified by washing first with 0.5% Triton X-100 in 150 mM NaCl, 10 mM EDTA, 10 mM Tris-HCl pH 7.5, then with 2 M urea in 100 mM Tris-HCl pH 8. Rabbits were immunized subcutaneously with approximately 500 ⁇ g of this partially purified fusion protein mixed with complete (first immunization) or incomplete Freund's adjuvant, every 2 weeks for a total of 3 injections.
  • Poly(A) + RNA for Northern analysis was isolated from cultured NHEK and normal human
  • RNA was resolved in a 1% agarose/formaldehyde gel
  • Double stranded cDNA in pGEM or pBluescript was sequenced in both directions by the dideoxy chain termination method with Sequenase (United States Biochemical Corp.). Oligonucleotides, corresponding to vector or previously-determined sequence, were synthesized to use as primers.
  • PC/Gene software (Intelligenetics) was used to determine: a) statistical significance of amino acid identities and similarities between corresponding regions of PVA with DGI and P-cadherin, as well as between extracellular domains of PVA (PCOMPARE), and b) transmembrane regions and signal peptides.
  • N-linked complex carbohydrates did not reside in, or depend on, N- linked complex carbohydrates.
  • the affinity-purified anti-PVA antibodies were used to screen a ⁇ gt11 library constructed from poly(A) + RNA extracted from NHEK cultured in 2.55 mM Ca 2+ . Of 10 6 recombinant clones, one (cDNA insert designated MJ315), which strongly bound the
  • MJ315 encodes epitopes that specifically bind PV antibodies. However, not all PV sera are capable of recognizing the limited epitopes expressed on immunoblots by the MJ315 fusior protein.
  • MJ315 encodes PVA by immunizing rabbits with the MJ315 fusion protein made in pUEX 1.
  • These rabbit antibodies stained monkey esophagus in the same cell surface pattern as PV sera (Fig 2D), and bound the 130-kD PVA by immunoblotting (data not shown).
  • immunofluorescence is limited to stratified squamous epithelia (Beutner et al., 1968), we determined whether mRNA for PVA was expressed in cells and tissues of stratified squamous epithelia
  • mRNA for PVA was detected only in stratified squamous epithelia (Fig. 5).
  • DNA sequencing of the overlapping PVA cDNA clones indicated a total 3,336 bp cDNA with a 2,997 bp open reading frame (Fig 7). There are two tandem ATG potential translation initiation codons after an upstream in-frame stop codon. Either could be the initiation codon, however the bases surrounding the second ATG codon are more consistent with a
  • Hydrophobicity plots also identified a putative transmembrane region. There is a stop codon at bases 3081-3, and two more in frame stop codons within 10 codons after it. There is a 256 bp, incomplete, 3 ' non-coding region .
  • cadherin By homology with cadherins, it can be deduced that the mature PVA protein is probably cleaved from a precursor protein after a conserved sequence of basic amino acids with the sequence R- R-X-K-R (Shirayoshi et al., 1986; Gallin et al., 1987; Goodwin et al., 1990; Koch et al., 1990;
  • homology to typical cadherins can be divided into 5 domains of about equal size (Figs 7,8), EC1 to EC5, which, except for EC5, have homology with each other.
  • EC1 to EC5 which, except for EC5 have homology with each other.
  • the homology is greatest among EC1, EC2 and EC3, the most amino- terminal domains (Ringwald et al., 1987; Takeichi, 1991).
  • the extracellular regions of DGI and desmocollin have been divided into 5 domains, only the first four of which in DGI are homologous to typical cadherins (Koch et al., 1990; Nilles et al., 1991; Collins et al., 1991; Mechanic et al., 1991). All five extracellular regions of PVA show significant homology to corresponding domains in P- cadherin. However, in domains EC1, EC2, and EC3 the homology of PVA to DGI is much greater than to P- cadherin. Unlike DGI, which has a shortened EC5 region, the EC5 region of PVA is similar in size to that of P-cadherin.
  • the cytoplasmic domain of PVA (360 amino acids) is substantially longer than that of typical cadherins (approximately 160 residues) but shorter than that of DGI (480 residues) .
  • PVA and DGI each have 5
  • cytoplasmic region of PVA can be divided into 4 subdomains. (Koch et al., 1990; Nilles et al., 1991) (Figs 7,8). PVA is missing a fifth glycine rich C-terminal cytoplasmic domain found in DGI (Koch et al., 1990; Nilles et al., 1991).
  • the IA ("intracellular anchor") region of PVA is homologous to that of DGI, but unlike that of typical cadherins, which have basic amino acids just inside the membrane.
  • the Cl region of PVA is similar to DGI and typical cadherins, but as with EC1-EC3, the similarity is much greater with DGI. Finally, the C3 region of PVA has two of the five N-V-X-V-T- E repeats that are found in DGI (Nilles et al., 1991).
  • Cadherins are Ca 2+ -dependent cell-cell adhesion molecules that mediate homophilic binding (Takeichi, 1991, 1990). These molecules are thought to be important in establishing and maintaining epithelial and neural tissue integrity.
  • the typical cadherins, which were the first defined, are now well
  • cadherins are also crucial for homophilic binding (Nagafuchi and Takeichi, 1988) as well as for binding catenins and CAP 102, cadherin- associated proteins that may anchor cadherins to the actin cytoskeleton (Ozawa et al., 1989, 1990;
  • PVA shows significant homology to all cadherins, but most markedly to DGI. This homology extends across species, suggesting that the
  • PVA has a putative signal sequence and a well conserved sequence of basic amino acids that presumably serve as a signal for cleavage to a mature protein.
  • PVA like typical cadherins, can be divided into five extracellular domains, of which EC1 to EC4 show variable homology to each other.
  • EC5 shows minimal or no significant homology to the other extracellular domains.
  • PVA shows much greater similarity to corresponding domains of DGI than to those of typical cadherins.
  • PVA has an R- A-L site in EC1 that corresponds to the conserved H- A-V site in an equivalent position in typical cadherins. PVA also has several conserved putative Ca 2+ binding domains with all cadherins as well as two conserved N-glycosylation sites with DGI.
  • Desmoglein shows extensive homology to the cadherin family of cell adhesion molecules. Biochem. Biophys. Res. Commun. 173 , 1224-1230.
  • Neural cadherin role in selective cell-cell adhesion. Science. 245 , 631-635.
  • E-cadherin cDNA Nature. 329 , 341-343. Nagafuchi, A. and Takeichi, M. (1988). Cell binding function of E-cadherin is regulated by the
  • keratinocytes the formation of keratinizing
  • Cadherin cell adhesion molecules with distinct binding specificities share a common structure. EMBO. J. 5, 2485-2488.
  • Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J. Clin. Invest. 70 , 281-288.
  • Cadherins a molecular family important in selective cell-cell adhesion.
  • N-cadherin gene maps to human chromosome 18 and is not linked to the E-cadherin gene. J. Neurochem. 55 , 805-812.
  • glycoprotein DGI a component of intercellular desmosome junctions, is related to the cadherin family of cell adhesion molecules. Proc. Natl. Acad. Sci. USA 88 , 4796-4800.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Pemphigus vulgaris (PV) is a life-threatening skin disease in which autoantibodies against a keratinocyte cell surface 130-kD glycoprotein, PV antigen (PVA), cause loss of cell-to-cell adhesion with resultant epidermal blisters. The present invention relates to DNA sequences encoding the entire amino acid sequence of PVA. The invention also relates to recombinant constructs containing the DNA sequence for PVA, and host cells transformed therewith. In addition, the invention relates to methods of diagnosing and treating persons afflicted with PV disease.

Description

NUCLEOTIDE AND AMINO ACID SEQUENCE
OF PEMPHIGUS VULGARIS ANTIGEN AND METHODS OF USE
BACKGROUND OF THE INVENTION Field of the Invention
The present invention relates, in general, to the molecular cloning and expression of a
glycoprotein, and, in particular, to pemphigus vulgaris antigen (PVA) which is involved in the autoimmune skin disease pemphigus vulgaris (PV).
The invention further relates to a cDNA sequence encoding PVA, to a recombinant DNA molecule that includes such a sequence and to cells transformed therewith. Background Information
Pemphigus vulgaris (PV) is an autoimmune disease or skin and mucous membranes in which autoantibodies against the keratinocyte cell surface cause loss of cell-to-cell adhesion and blister formation (Stanley, 1989). PV antigen (PVA), which is defined by autoantibodies from these patients, has been characterized by immunoprecipitation and immunoblotting as a 130-kD glycoprotein (Stanley et al., 1982, 1984; Eyre and Stanley, 1988; Jones et al., 1986; Hashimoto et al., 1990). All patients with PV, but not normals or other disease control patients, have antibodies that bind this
glycoprotein. More recent studies (Korman et al., 1989) have shown that in extracts of normal human epidermis PVA is linked by disulfide bonds to plakoglobin, an 85-kD molecule found in the plaque of the desmosome and cell-to-cell adherens junction (Cowin et al., 1986). Immunoelectron microscopic studies have shown that, although PVA is present in desmosomes, it is probably also present as well along the entire cell surface of keratinocytes (Wolff and Schreiner, 1971; Jones et al., 1986b).
Several observations and studies have demonstrated that the autoantibodies from PV patients are pathogenic: 1) Disease activity in PV patients often correlates with anti-cell surface antibody titer, as determined by indirect
immunofluorescence (Sams and Jordon, 1971). 2) Neonates of mothers with PV may have transient disease due to maternal IgG which crosses the placenta (Merlob et al., 1986). As maternal antibody is catabolized, disease subsides. 3) PV IgG alone, without complement or inflammatory cells, can cause loss of cell-to-cell adhesion, with the same
histology as seen in PV blisters, in skin organ culture (Schiltz and Michel, 1976; Hashimoto et al., 1983). 4) Passive transfer of PV IgG to neonatal mice results in loss of cell-to-cell adhesion and blisters with typical PV histology (Anhalt et al., 1982).
SUMMARY OF THE INVENTION
Because PV autoantibodies cause loss of cell adhesion, we speculated that PVA might be a cell adhesion molecule (Jones et al., 1986b). To address this question, we cloned the cDNA encoding PVA using patients' antibodies. We used affinity- purified PV IgG to isolate cDNA, containing the entire coding sequence for PVA, from human
keratinocyte expression libraries. Northern
analysis indicated PV mRNA expression only in stratified squamous epithelia. The deduced amino acid sequence of PVA was unique but showed
significant homology to members of the cadherin family of Ca2+-dependent cell adhesion molecules, most markedly to desmoglein I. These findings demonstrate that a novel epithelial cadherin is the target of autoantibodies in PV, a disease of
epidermal cell adhesion. The DNA sequence and clones can be used for diagrostic purposes. For example, pemphigus vulgaris antigen proteins have been made from the cDNA and these proteins have been used to raise antibodies. These proteins can also be used in ELISA assays for detection of
autoantibodies to diagnose pemphigus vulgaris.
These sequences could also be used for specific therapy by using proteins derived from them for specific plasmapheresis.
Accordingly, it is an object of the present invention to provide a DNA fragment that encodes pemphigus vulgaris antigen.
It is another object of the present invention to provide an amino acid sequence for the pemphigus vulgaris antigen.
It is a further object of the present invention to provide a recombinantly produced, biologically stable pemphigus vulgaris antigen glycoprotein.
It is yet another object of the present invention to provide a recombinant DNA construct comprising a vector, and the above-described DNA fragment.
It is a further object of the present invention to provide a host cell transformed with the above-described recombinant DNA construct.
It is another object of the present invention to provide a method of producing pemphigus vulgaris antigen which comprises culturing a host cell under conditions such that the above- described DNA fragment is expressed and pemphigus vulgaris antigen is thereby produced, and isolating pemphigus vulgaris antigen.
It is a further object of the present invention to provide an antibody to the above- described recombinant pemphigus vulgaris antigen.
It is another object of the present invention to provide a method of detecting the presence of pemphigus vulgaris antigen in a sample comprising the steps of contacting the sample with the above-described antibody, and detecting the presence or absence of a complex formed between the pemphigus vulgaris antigen and the antibody.
It is yet another object of the present invention to provide a method for the diagnosis of pemphigus vulgaris disease comprising the steps of:
(i) coating a surface with all, or a unique portion, of the above-described recombinantly produced pemphigus vulgaris antigen,
(ii) contacting the coated surface with serum from an individual suspected of having the disease; and
(iii) detecting the presence or absence of a complex formed between the pemphigus vulgaris antigen and antibodies specific therefor present in the serum.
It is a further object of the present invention to provide a diagnostic kit comprising a recombinantly produced pemphigus vulgaris antigen and ancillary reagents suitable for use in detecting the presence of antibodies to pemphigus vulgaris antigen in mammalian serum or tissue samples.
It is an object of the present invention to provide a therapeutic method for the treatment of pemphigus vulgaris disease comprising performing plasmapheresis on an individual having pemphigus vulgaris disease, wherein the above-described recombinantly produced pemphigus vulgaris antigen is contacted with the individual's blood prior to reinfusion of the blood into the individual.
Other objects of the present invention will be apparent by the description of the
embodiments that follows.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. PVA immunoprecipitated from keratinocytes cultured with (+) and without (-) tunicamycin.
Immunoprecipitations were performed with either PV or, as controls, normal (N) sera. Arrow shows 130- kD glycosylated PVA. Arrowhead shows that PVA precipitated from extracts of cells cultured with tunicamycin, which inhibits N-glycosylation,
migrates faster, at about 115 kD. (The bars on the right indicate migration of molecular weight
standards, 200, 116, 97, and 66 kD). Figure 2. Immunofluorescence of PVA on monkey esophagus.
(A) PV IgG affinity-purified on immunoblots of the 130-kD PVA. (B) PV IgG affinity-purified by epitope selection on the fusion protein produced by clone MJ315. (C) Control for B, epitope selection of PV serum by irrelevant clones. (D) Rabbit antibodies raised against the MJ315 fusion protein.
(Magnification x 136).
Figure 3. Immunoblot of NHEK extracts with PV serum and PV IgG affinity-purified on the 130-kD PVA and on the MJ315 clone.
Lane 1: PV serum binds the 130-kD PVA (arrowhead) as well as other bands. Lane 2: PV IgG affinity- purified on PVA binds only the 130-kD PVA. Lane 3: PV IgG affinity-purified by epitope selection on clone MJ315 binds PVA. Lane 4: control for lane 3, epitope selection of PV serum by irrelevant clones does not result in binding on the immunoblot.
(Molecular weight standards, indicated by bars are 200, 116, and 97 kD).
Figure 4. Specificity of PV binding to immunoblot of the MJ315 fusion protein.
Immunoblot of the MJ315 fusion protein produced in pUEX 1 with PV, pemphigus foliaceous (PF), bullous pemphigoid (BP), and normal (N) sera. Only PV sera bind the fusion protein (arrow). (Molecular weight standards indicated by bars are 200, 116, and 97 kD).
Figure 5. Northern analysis of PVA.
Northern blots of poly(A)+ RNA with MJ315 cDNA
(lanes 1-17) and human β-actin cDNA (below lanes 1- 10, 13-17, to show relative amounts of RNA on each lane). Lane 1-NHEK; lanes 2,3-cultured human
fibroblasts. The major mRNA for PVA is approximately 6 kb (arrow), and minor bands at approximately 4 and 3.5 kb are also seen. Lane 4-NHEK, positive control for PVA mRNA; lane 5-human brain; lane 6- human heart; lane 7-human lung; lane 8-human liver; lane 9-human kidney; lane 10-human placenta. (Lanes 4-10 were exposed for 15 hr, and corresponding actin lanes were exposed for 2 hr. Even when exposed for 72 hr, lanes 5-10 did now show PVA mRNA) . Lane 11- monkey esophagus and lane 12-monkey tongue show PVA mRNA (approximately 6 kb) in these stratified squamous epithelia. Lane 13-monkey tongue, positive control for PVA mRNA; lane 14-monkey liver; lane 15- monkey lung; lane 16-monkey small intestine; lane 17-monkey kidney. (Lanes 13-17, and corresponding actin lanes, exposed for 8 hr. Although the actin mRNA loading is light for monkey liver and lung, even with exposures up to 72 hr, these tissues do not show PVA mRNA). Lines to right of lanes 3 and 12 indicate RNA standards of 9.5, 7.5, 4.4, 2.4, and 1.4 kb. Figure 6. Southern analysis of PVA.
Southern blot of human placental DNA digested with indicated restriction enzymes and hybridized to MJ315. (DNA size markers, indicated by bars, are 9.4, 6.6, 4.4, 2.3, and 2.0 kb). Figure 7. Nucleotide and predicted amino acid sequence of PVA.
The putative signal sequence and transmembrane domain are marked by a dashed and double underline, respectively. The p asumed recognition site for proteolytic cleavage is underlined. The R-A-L sequence, which corresponds to the H-A-V sequence of typical cadherins is boxed. Putative Ca2+-binding sites are shaded. Horizontal arrows under the amino acid sequence show beginning of each domain.
Horizontal arrows over nucleotide sequence indicate regions of isolated clones. Vertical arrows indicate potential N-glycosylation sites. * indicates stop codon. (GenBank accession number M76482).
Figure 8. Multiple amino acid sequence alignment of human PVA (pv), human DGI (dg), and human P-cadherin (pc) . DGI (Nilles et al . , 1991) and P-cadherin
(Shimoyama et al., 1989) are from published sequences. The sequences for each molecule start with the proteolytic cleavage recognition site then are divided into domains, as explained in the text. (The amino acid numbers for these domains are found in Figure 7). Amino acid residues of PVA that are conserved in DGI or P-cadherin are shaded. Solid lines overlie putative Ca2+-binding sites. Vertical arrows indicate potential N-glycosylation sites shared by PVA and DGI. *'s indicate R-A-L sequence of PVA and DGI that corresponds to P-cadherin's H- A-V sequence. Cysteine residues of PVA that are conserved in DGI or P-cadherin are shown in reverse highlight. The + ' s indicate the repetitive N-V/Y-X- V-T-E domains shared by PVA and DGI. The identity and similarity of DGI and P-cadherin to PVA are shown for each domain to the right of the sequences. (NS indicates that similarity is not significant).
DETAILED DESCRIPTION OF THE INVENTION
This invention relates to a glycoprotein, phemphigus vulgaris antigen (PVA), that is involved in the disease pemphigus vulgaris (PV), an
autoimmune disease of skin and mucous membranes in which autoantibodies against the surface of
keratinocyte cells cause loss of cell-to-cell adhesion and blister formation. The autoantibodies are specific to PVA, which has been characterized as a 130-kD glycoprotein linked by disulfide bonds to plakoglobin.
In one embodiment, this invention relates to DNA sequences (including cDNA sequences) that encode PVA. The invention further relates to DNA sequences that encode the entire amino acid sequence given in Figure 7 (the specific DNA sequence given in Figure 7 being only one example), or any portion comprising at least 12 base pairs thereof. DNA sequences to which the invention relates also include those encoding proteins (or polypeptides) having substantially the same autoantibody binding characteristics of PVA (for example, allelic forms of the amino acid sequence of Figure 7).
That the cDNA cloned encodes the 130-kD PVA is supported by several observations, as
demonstrated by the examples below: 1) PV sera, but not normal or disease control sera, bind the fusion protein derived from the initially isolated clone (MJ315) 2) Epitope selection of antibodies from PV sera by this clone resulted in IgG that stained monkey esophagus by immunofluorescence in the same cell surface pattern as do PV sera, and that bound the 130-kD PVA.
3) Rabbit sera raised against the MJ315 fusion protein also showed PV-like immunofluorescence and bound the 130-kD PVA by immunoblotting 4) Extension clones E12 and E33, as well as initial clone MJ315, hybridized to the same size mRNAs, which were large enough to encode the PVA 5) The tissue specificity of mRNA expression for PVA is consistent with the known tissue distribution of PVA (i.e. stratified squamous epithelia only). 6) The initial and
extension clones contain one long continuous open reading frame encoding a protein of approximately the correct molecular weight and isoelectric point.
In another embodiment, the present
invention also relates to proteins (or polypeptides) having an amino acid sequence corresponding to any portion that is at least 4 amino acids of the protein depicted in Figure 7 (or allelic variations thereof). As an example, the protein (or
polypeptide) can have an amino acid sequence corresponding to an epitope of the sequence of Figure 7 (or allelic variation thereof).
Furthermore, the protein can be used as an antigen, in protocols known in the art, to produce antibodies thereto, both monoclonal and polyclonal.
In another embodiment, the present
invention relates to a recombinant DNA molecule that includes a vector and a DNA sequence as described above (advantageously, a DNA sequence encoding the protein shown in Figure 7 or a protein having the autoantibody binding characteristics of that
protein). The vector can take the form of a virus, a plasmid, or eukaryotic expression vector (for example, lambda gTII, pUEX, bacillovirus vectors and pcDNAIneo expression vectors). The DNA sequence can be present in the vector operably linked to
regulatory elements, including, for example, a promoter. The recombinant molecule can be suitable for transforming procaryotic or transfecting
eukaryotic cells, advantageously, mammalian cells or insect cells. For instance, pUEX plasmids are suitable for transforming bacterial cells, and pcDNAIneo vector is suitable for eukaryotic
transfection.
In a further embodiment, the present invention relates to host cells stably transformed or transfected with the above-described recombinant constructs. The host cell can be prokaryotic (for example, bacterial), lower eukaryotic (for example, yeast or insect) or higher eukaryotic (for example, all mammals, including but not limited to mouse and human). For instance, transient or stable
transfections can be accomplished into Chinese hamster ovary cells (CHO) or COS-7 cells.
Transformation or transfection can be accomplished using protocols and materials well known in the art. The transformed or transfected host cells can be used as a source of the DNA sequences described above (which sequence constitutes part of the recombinant construct). When the recombinant molecule takes the form of an expression system, the transformed or transfected cells can be used as a source for the above-described PVA protein.
In a further embodiment, the present invention relates to a method of producing PVA which includes culturing the above-described host cells, under conditions such that the DNA fragment is expressed and PVA is produced thereby. The PVA can then be isolated using methodology well known in the art. The PVA produced can be used in the diagnosis or treatment of persons having PV.
In another embodiment, the present
invention relates to antibodies specific for the above-described proteins (or polypeptides). For instance, an antibody can be raised against a peptide having the amino acid sequence of Figure 7 , or against a portion thereof of at least 4 amino acids in length. Persons skilled in the art using standard methodology can raise monoclonal and polyclonal antibodies to the protein (or
polypeptide), or a unique portion thereof.
In a further embodiment, the present invention relates to a method of detecting the presence of PVA or antibodies against PVA in a sample. Using standard methodology well known in the art, a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), all or a unique portion of the synthetic PVA protein described above, and contacting it with the serum of a person suspected of having PV. The presence of a resulting complex formed between the PVA and antibodies specific therefor in the serum can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colorimetry. This method of detection can be used, for example, for the diagnosis of PV.
In another embodiment, the present
invention relates to a diagnostic kit which contains recombinantly produced PVA and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence of antibodies to PVA in serum or a tissue sample. Tissue samples contemplated can be monkey and human, or other mammals such as dog.
In a further embodiment, the present invention relates to a therapeutic method for the treatment of PV disease. Plasmapheresis can be conducted on an individual having PV. Before reinfusion of the blood back into the individual, persons skilled in the art using standard
methodology can contact the individual's blood with the synthetic PVA described above. The blood can then be reinfused into the individual.
EXAMPLES
The following technical protocols and materials are used in the examples that follow:
Human Sera
Sera from patients with clinically and histologically typical PV showed characteristic cell surface immunofluorescence on monkey esophagus and immunoprecipitated the 130-kD PVA (Stanley, 1989). Control sera were obtained from patients with clinically and histologically typical pemphigus foliaceous and bullous pemphigoid. These sera also showed characteristic immunofluorescence findings (Stanley, 1989). Finally, normal human sera were also used as controls. Cell Culture
NHEK (Clonetics) were culture in keratinocyte grovth medium (Clonetics) nich has a Ca2+ concentratic. of 0.15 mM. In some experiments the Ca2+ concentration was raised to 2.55 mM for 24 hr before RNA extraction and for 48 hr before indirect immunofluorescence. To determine the effects of N-glycosylation on the immunoreactivity of PVA, human foreskin epidermal cells were cultured on 3T3 cells as previously described (Rheinwald and Green, 1975; Fuchs and Green, 1981; Stanley et al., 1984), either with or without 2.5 μg/ml tunicamycin (Sigma), which was added for 1 hr before the
addition of 14C-amino acids. Cells were radiolabeled overnight, then extracted for immunoprecipitation, as previously described (Stanley et al., 1984). Tmmunofluorescence
Indirect immunofluorescence with PV sera or rabbit antisera was performed on monkey
esophagus, the standard substrate to detect PVA with patients' sera, or on cultured NHEK as previously described (Sabolinski et al., 1987; Stanley et al., 1981, 1982).
Tmmunoblotting and Affinity Purification of PV IgG
Proteins from cultured NHEK were extracted with sodium dodecyl sulfate (SDS) sample buffer with reduction, separated by SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to
nitrocellulose membranes (Hashimoto et al., 1990; Towbin et al., 1979). Immunoblotting was performed with human sera or rabbit antisera and alkaline phosphatase labeled goat anti-human or anti-rabbit IgG (Stanley et al., 1984; Amagai et al., 1990). For affinity purification of PV IgG, horizontal strips of nitrocellulose containing the 130-kD PVA were cut out, incubated wtih PV serum, washed, then bound antibodies were eluted with acid glycine buffer, neutralized, dialyzed against phosphate buffered saline, and concentrated as described (Mueller et al., 1989). Construction and screening of cDNA Library
Total RNA was extracted from cultured NHEK with LiCl buffer (Amagai et al., 1990) and poly(A)+ RNA was purified twice with an oligo(dT) column
(Stratagene). cDNA was synthesized with random primers and the reverse transcriptase Superscript (Gibco-BRL) by the basic method of Gubler and
Hoffman (Gubler and Hoffman, 1983). The cDNA was ligated with EcoRI/NotI adaptors (Invitrogen) in order to insert into the EcoRl site of λgt11 (Young and Davis, 1983) or λZap11 (Stratagene) then
packaged (Stratagene). Approximately 106 independent recombinants were screened by immunostaining (Amagai et al., 1990) using affinity-purified PV antibodies. Positive clones were plaque-purified through several rounds of re-screening.
For extension cloning, the cDNA library was screened at high stringency by hybridization with MJ315 labeled with 32P by random primer labeling (Maniatis et al., 1982). From approximately 106 recombinant clones, E12 and E33 were isolated, and plaque purified.
The cDNA inserts from these purified plaques were subcloned into the plasmid vector pGEM
(Promega) or pBluescript (Stratagene) for further characterization.
Epitope Selection
Plaque lifts of nitrocellulose-bound fusion protein produced by MJ315 in λgt11 were used to affinity purify antibodies from the PV serum as described previously (Stanley et al., 1988).
Rabbit Immunization with MJ315 Fusion Protein
The MJ315 cDNA insert was excised from its pGEM plasmid vector by amplification with polymerase chain reaction (PCR) with primers that annealed to both ends and that included either a BamHI or PstI site, so that the insert could be directionally subcloned, in frame, into the BamHI-PstI site of the expression plasmid vector pUEX 1 (Amersham). The crude β-galactosidase fusion protein produced by pUEX was isolated as previously described for fusion proteins produced in pEX (Tanaka et al., 1990). The precipitated fusion protein was then partially purified by washing first with 0.5% Triton X-100 in 150 mM NaCl, 10 mM EDTA, 10 mM Tris-HCl pH 7.5, then with 2 M urea in 100 mM Tris-HCl pH 8. Rabbits were immunized subcutaneously with approximately 500 μg of this partially purified fusion protein mixed with complete (first immunization) or incomplete Freund's adjuvant, every 2 weeks for a total of 3 injections.
Northern and Southern Blot Analysis
Poly(A)+ RNA for Northern analysis was isolated from cultured NHEK and normal human
fibroblasts as described above. Poly (A)+ RNA was also extracted from monkey esophagus and tongue
(Invitrogen Fast Track System). Poly(A)+ RNA from human and other monkey tissues were also used
(Clontech). Approximately 2 μg of each RNA was resolved in a 1% agarose/formaldehyde gel,
transferred by blotting to a nylon membrane
(Genescreen Plus, Dupont), and hybridized at 42° in 50% formamide with 32P-labeled MJ315 cDNA (Amagai et al., 1991). Duplicate lanes of RNA, run in parallel, were used for 32P-labeled 0-actin cDNA hybridization.
For Southern analysis, human
placental DNA (Oncor) was digested with EcoRl,
Hindlll, BamHI, Pstl, and Bglll and electrophoresed in a 0.7% agarose gel, then transferred by vacuum blotting to a nylon membrane and hybridized to 32P- labeled MJ315, as described (Amagai et al., 1991). Sequence Analysis
Double stranded cDNA in pGEM or pBluescript was sequenced in both directions by the dideoxy chain termination method with Sequenase (United States Biochemical Corp.). Oligonucleotides, corresponding to vector or previously-determined sequence, were synthesized to use as primers.
Homology searches against GenPep (Release 64.3), PIR-Protein (Release 28), SwissProt (Release 18) with FASTA, sequencer-comparison with GAP, and multiple sequence alignment with PILEUP were done with the University of Wisconsin Genetics Computer Group software on a VAX (Devereux et al., 1984).
PC/Gene software (Intelligenetics) was used to determine: a) statistical significance of amino acid identities and similarities between corresponding regions of PVA with DGI and P-cadherin, as well as between extracellular domains of PVA (PCOMPARE), and b) transmembrane regions and signal peptides. Example I
Further Characterization of PVA and Affinity
Purification of PV IgG to Optimize Cloning
To determine if we could screen prokaryotic expression vectors with PV sera, we wanted to be sure that the antigenic moiety of the
PVA glycoprotein did not reside in, or depend on, N- linked complex carbohydrates. We therefore cultured NHEK in the presence or absence of tunicamycin, which blocks N-glycosylation, and immunoprecipitated extracts of these cells with PV sera. From cells cultured with or without tunicamycin, PV sera specifically precipitated approximately 115-kD and 130-kd molecules, respectively (Fig. 1). Therefore, we conclude that N-linked sugars add about 15 kD to the molecular weight of PVA and the antigenic specificity of PV antibodies does not depend on N- glycosylation.
We, therefore, used sera from patients with PV to screen a λgt11 expression library of cDNA obtained from normal human epidermal keratinocytes (NHEK) cultured in 0.15 mM Ca2+ medium. Preliminary immunoprecipitation studies showed that these cells synthesize PVA (data not shown). Over 200 candidate clones were identified by various PV sera, but none of these could be confirmed to be correct, because although the protein products of these clones bound the PV screening serum, either they also bound other normal or disease control sera or they did not bind any other PV sera. Therefore we tried to optimize our cloning procedure to yield more λ colonies encoding PVA and to use antibodies which would result in fewer false positive clones.
Data with mouse keratinocytes suggest that PVA synthesis is increased by raising the Ca2+ concentration of the growth medium (Stanley and Yuspa, 1983). We found similar results, as
determined by immunofluorescence and
immunoprecipitation, with these human cells, and therefore used keratinocytes grown in 2.55 mM Ca2+ for 24 hr for constructing a λgt11 cDNA library.
Finally, to decrease the detection of false positive clones by whole sera from PV
patients, we affinity-purified a PV serum on
immunoblots of the 130-kD PVA. This affinity- purified IgG stained the cell surface of monkey esophagus epithelial cells (Fig 2A) in the same pattern as do PV sera and bound only the 130-kD PVA on immunoblots, whereas the whole sera bound additional bands (Fig 3, lanes 1,2).
Example II
Isolation of cDNA Clones for PVA
The affinity-purified anti-PVA antibodies were used to screen a λgt11 library constructed from poly(A)+ RNA extracted from NHEK cultured in 2.55 mM Ca2+. Of 106 recombinant clones, one (cDNA insert designated MJ315), which strongly bound the
affinity-purified PVA antibodies, but not normal human sera, was characterized further. The 0.7 kb MJ315 cDNA insert was sequenced and found to contain one continuous open reading frame (Fig 7). The cDNA was then subcloned, in frame, into the expression plasmid pUEX 1. The MJ315-β-galactosidase fusion protein was produced and tested by immunoblotting with PV sera, as well as pemphigus foliaceous and bullous pemphigoid disease control sera and normal sera. (Pemphigus foliaceous and bullous pemphigoid are autoantibody-mediated blistering skin diseases, whose autoantigens are distinct from PVA (Stanley, 1989)). This fusion protein was recognized by 7 out of 23 PV sera, but not by any of 19 pemphigus foliaceous, 14 bullous pemphigoid or 10 normal sera (Fig 4). We conclude that MJ315 encodes epitopes that specifically bind PV antibodies. However, not all PV sera are capable of recognizing the limited epitopes expressed on immunoblots by the MJ315 fusior protein.
To confirm that the antibodies which bind to the protein encoded by MJ315 also bind to the cell surface of stratified squamous epithelial cells and the 130-kD PVA, we used epitope selection to affinity-purify the IgG from PV serum incubated on the λ clone of MJ315. This affinity-purified IgG, but not IgG affinity purified from PV serum on irrelevant clones, showed cell surface
immunofluorescence on monkey esophagus epithelium, indistinguishable from that of PV sera (Fig 2B,C), and bound the 130-kD PVA on immunoblots (Fig 3, lanes 3,4).
Finally, we confirmed that MJ315 encodes PVA by immunizing rabbits with the MJ315 fusion protein made in pUEX 1. These rabbit antibodies stained monkey esophagus in the same cell surface pattern as PV sera (Fig 2D), and bound the 130-kD PVA by immunoblotting (data not shown).
In order to isolate cDNA with the entire coding sequence for PVA, we screened λgt11 and λZAPII keratinocyte cDNA libraries with 32P-labeled MJ315 and the 5' 200 bp of MJ315. We isolated two extended, overlapping clones (cDNA inserts
designated E12 and E33), which contained the entire coding region of PVA (Fig 7).
Example III
Northern and Southern Analysis
Northern analysis of mRNA extracted from cultured NHEK with MJ315, E12, or E33 each indicated a major 6 kb and minor 4 and 3.5 kb bands (Fig 5). The size of the RNA is large enough to encode a 115 kD protein. Because the detection of PVA by
immunofluorescence is limited to stratified squamous epithelia (Beutner et al., 1968), we determined whether mRNA for PVA was expressed in cells and tissues of stratified squamous epithelia
(keratinocytes, esophagus, tongue) compared to other cells and tissues (fibroblasts, brain, heart, lung, liver, kidney, placenta, and small intestine). mRNA for PVA was detected only in stratified squamous epithelia (Fig. 5).
Southern analysis of human genomic DNA digested with EcoRl, Hindlll, and PstI and
hybridized with MJ315 showed a single band, which suggests that PVA is encoded by a single gene (Fig. 6).
Example IV
Analysis of the Deduced Amino Acid Sequence of PVA and Comparison with Cadherin Family
DNA sequencing of the overlapping PVA cDNA clones indicated a total 3,336 bp cDNA with a 2,997 bp open reading frame (Fig 7). There are two tandem ATG potential translation initiation codons after an upstream in-frame stop codon. Either could be the initiation codon, however the bases surrounding the second ATG codon are more consistent with a
consensus initiation sequence (Kozak, 1987). Either one of the potential initiation methionines starts what is predicted to be a hydrophobic signal
sequence. Hydrophobicity plots also identified a putative transmembrane region. There is a stop codon at bases 3081-3, and two more in frame stop codons within 10 codons after it. There is a 256 bp, incomplete, 3 ' non-coding region .
Comparison of the PVA amino acid sequence to protein databases indicated significant homoloyy only to members of the cadherin family, most
markedly to DGI. The overall similarity/identity of PVA to human (Wheeler et al., 1991; Nilles et al., 1991) and bovine DGI (Koch et al., 1990; Goodwin et al., 1990) was 64%/46% and 65%/48%, respectively. There was also significant similarity/identity to the typical cadherins: human P-cadherin (Shimoyama et al., 1989) 47%/25%, mouse P-cadherin (Nose et al., 1987) 48%/25%, human N-cadherin (Walsh et al., 1990) 47%/29%, chick N-cadherin (Hatta et al., 1988) 48%/28%. This similarity of PVA to the typical cadherins was about the same as to the recently cloned bovine desmocollins I/II (Collins et al., 1991; Mechanic et al., 1991), also of the cadherin family: 47%/28%. We conclude that PVA is a member of the cadherin family, and that it is more closely related to DGI than to the typical cadherins. Since this similarity is the same across species lines, it suggests that the conserved areas may subserve important functions.
These conserved areas are demonstrated in
Fig 8, in which PVA is compared with human DGI and human P-cadherin, a representative, typical
cadherin. By homology with cadherins, it can be deduced that the mature PVA protein is probably cleaved from a precursor protein after a conserved sequence of basic amino acids with the sequence R- R-X-K-R (Shirayoshi et al., 1986; Gallin et al., 1987; Goodwin et al., 1990; Koch et al., 1990;
Collins et al., 1991; Mechanic et al., 1991; Ozawa and Kemler, 1990) (Figs. 7,8). This cleavage would result in a mature PVA unglycosylated peptide of 950 amino acids with molecular weight 102 kD and pI 4.5. This is in fairly good agreement with the estimated molecular weight of PVA extracted from cells
cultured with tunicamycin (Fig. 1) and with a pI for PVA estimated at 5 (Eyre and Stanley, 1988).
The extracellular region of PVA, by
homology to typical cadherins (Hatta et al., 1988; Shimoyama et al., 1989), can be divided into 5 domains of about equal size (Figs 7,8), EC1 to EC5, which, except for EC5, have homology with each other. As for typical cadherins, the homology is greatest among EC1, EC2 and EC3, the most amino- terminal domains (Ringwald et al., 1987; Takeichi, 1991). Similarly, the extracellular regions of DGI and desmocollin have been divided into 5 domains, only the first four of which in DGI are homologous to typical cadherins (Koch et al., 1990; Nilles et al., 1991; Collins et al., 1991; Mechanic et al., 1991). All five extracellular regions of PVA show significant homology to corresponding domains in P- cadherin. However, in domains EC1, EC2, and EC3 the homology of PVA to DGI is much greater than to P- cadherin. Unlike DGI, which has a shortened EC5 region, the EC5 region of PVA is similar in size to that of P-cadherin. The highly conserved sequence H- A-V of typical cadherins (Takeichi, 1990), thought to be important in cell adhesion (Blaschuk et al., 1990; Nose et al., 1990), is represented in PVA and DGI by the conservatively substituted sequence R-A- L (Figs 7,8) (Koch et al., 1990; Goodwin et al., 1990; Wheeler et al., 1991).
Other conserved sequences in the extracellular domains of PVA and cadherins with potential function include putative Ca2+-binding motifs (D-X-N-D-N and A/V-X-D-X-D) (Figs 7,8)
(Ringwald et al., 1987; Ozawa et al., 1990). In addition, 2 of 4 potential N-glycosylation sites in PVA are conserved in equivalent positions in DGI (Fig 8).
The cytoplasmic domain of PVA (360 amino acids) is substantially longer than that of typical cadherins (approximately 160 residues) but shorter than that of DGI (480 residues) . Unlike typical cadherins, which do not contain cysteines in the cytoplasmic domain, PVA and DGI each have 5
cysteines in equivalent positions (Fig 8). By homology with DGI the cytoplasmic region of PVA can be divided into 4 subdomains. (Koch et al., 1990; Nilles et al., 1991) (Figs 7,8). PVA is missing a fifth glycine rich C-terminal cytoplasmic domain found in DGI (Koch et al., 1990; Nilles et al., 1991). The IA ("intracellular anchor") region of PVA is homologous to that of DGI, but unlike that of typical cadherins, which have basic amino acids just inside the membrane. The Cl region of PVA is similar to DGI and typical cadherins, but as with EC1-EC3, the similarity is much greater with DGI. Finally, the C3 region of PVA has two of the five N-V-X-V-T- E repeats that are found in DGI (Nilles et al., 1991).
Since autoantibodies in PV patients have been shown to mediate loss of epidermal cell
adhesion with resultant blister formation, it seems particularly relevant that analysis of the deduced amino acid sequence for PVA indicated homology to the cadherin family of cell adhesion molecules.
Cadherins are Ca2+-dependent cell-cell adhesion molecules that mediate homophilic binding (Takeichi, 1991, 1990). These molecules are thought to be important in establishing and maintaining epithelial and neural tissue integrity. The typical cadherins, which were the first defined, are now well
characterized at a molecular level and include E- cadherin (Ringwald et al., 1987; Nagafuchi et al., 1987), N-cadherin (Hatta et al., 1988; Miyatani et al., 1989; Walsh et al., 1990), P-cadherin (Nose et al., 1987; Shimoyama et al., 1989), and L-CAM
(Gallin et al., 1987). These form a closely related family of molecules with very well conserved extracellular and cytoplasmic domains (Takeichi, 1991, 1990). Studies utilizing monoclonal antibody inhibition of homophilic binding, site-directed mutagenesis, and production of chimeric cadherin molecules have shown that the amino terminal 113 residues are important for determining binding function and specificity of binding (Nose et al., 1990; Takeichi, 1990). Calcium binding to the first Ca2+-binding motif in EC2 has also been shown to be critical for preserving adhesive function (Ozawa et al., 1990). In addition, the very well conserved cytoplasmic portion of cadherins is also crucial for homophilic binding (Nagafuchi and Takeichi, 1988) as well as for binding catenins and CAP 102, cadherin- associated proteins that may anchor cadherins to the actin cytoskeleton (Ozawa et al., 1989, 1990;
Nagafuchi et al., 1991).
Recently DGI and desmocollins,
transmembrane glycoproteins that extend into the core of desmosomes (Gorbsky and Steinberg, 1981;
Mueller and Franke, 1983; Cowin et al., 1984; Miller et al., 1987; Steinberg et al., 1987), have been cloned (Koch et al., 1990; Goodwin et al., 1990; Wheeler et al., 1991; Nilles et al., 1991; Collins et al., 1991; Mechanic et al., 1991). Both were found to be related to typical cadherins in their extracellular domains and part of their cytoplasmic portions. Desmocollins are no more similar to DGI than to typical cadherins. Although PVA may also be found in desmosomes, it is not necessarily
concentrated in these junctions, but may be found uniformly on the keratinocyte cell surface (Wolff and Schreiner, 1971; Jones et al., 1986b).
PVA shows significant homology to all cadherins, but most markedly to DGI. This homology extends across species, suggesting that the
conserved regions may be functionally important. Like all other members of the cadherin family, PVA has a putative signal sequence and a well conserved sequence of basic amino acids that presumably serve as a signal for cleavage to a mature protein. PVA, like typical cadherins, can be divided into five extracellular domains, of which EC1 to EC4 show variable homology to each other. Like typical cadherins, EC5 shows minimal or no significant homology to the other extracellular domains. Near the amino terminus of the mature protein, which is the area containing important sites for homophilic binding in typical cadherins, PVA shows much greater similarity to corresponding domains of DGI than to those of typical cadherins. Like DGI, PVA has an R- A-L site in EC1 that corresponds to the conserved H- A-V site in an equivalent position in typical cadherins. PVA also has several conserved putative Ca2+ binding domains with all cadherins as well as two conserved N-glycosylation sites with DGI.
Glycosylation at the four potential extracellular N- glycosylation sites of PVA could account for the 15 kD difference in molecular weight of PVA synthesized in the presence or absence of tunicamycin. The cytoplasmic domains of PVA are also most similar to those of DGI. Most remarkably, PVA and DGI share 5 cysteines in equivalent positions, whereas typical cadherins lack cysteines. This could be significant in that PVA, like DGI, binds plakoglobin by
disulfide bonds (Korman et al., 1989), whereas typical cadherins bind catenins and CAP 102
presumably by noncovalent bonds (Ozawa et al., 1989, 1990; Nagafuchi et al., 1991). These sequence comparison data indicate that DGI and PVA are both in the cadherin family of proteins, but are more closely related to each other than to typical cadherins or to desmocollins. Thus, PVA and DGI form a subfamily of cadherins.
Like PVA, DGI is also a target antigen in another autoantibody-mediated blistering disease of the epidermis, pemphigus foliaceous (Koulu et al., 1984; Stanley et al., 1986; Eyre and Stanley, 1987). Pemphigus foliaceous is clinically and
histologically distinct from PV. The blister in pemphigus foliaceous occurs more superficially within the epidermis than does the blister in PV. As in PV, pemphigus fold seous autoantibodies have been shown to mediate loss of cell adhesion and blister formation (Hashimoto et al., 1983; Roscoe et al.,
1985; Rock et al., 1 990). Thus, in the two known IgG autoantibody-mediated blistering diseases of
epidermis, cadherin-like molecules are the target antigens. However, from previous immunofluorescence studies as well as the Northern data presented here, expression of PVA is limited to stratified squamous epithelia, whereas DGI is present in all desmosomecontaining tissues (Cowin and Garrod, 1983; Schmelz et al., 1986). Alternatively, PVA might be
considered to be a tissue-specific type of
desmoglein. In an case, autoantibodies from PV patients define a novel cadh in, l d to
stratified squamous epithelia, and
Figure imgf000029_0001
get of an autoimmune disease that results in blisters in these tissues. These find suggest that vel
cadherin is importa the nal ture and maintenance of adul
Figure imgf000029_0003
dermis and c
Figure imgf000029_0002
a target of disease.
Although various pathophysiologic mechanisma of blister formation have been proposed in PV (Hashimoto et al., 1983; Morioka et al., 1987; Sams and Gammon, 1982), it must now be considered that autoantibodies in these patients may interfere directly with the function of PVA as an adhesion molecule. Cloning of PVA, and the fact that there is a good animal model for inducing the disease with passive transfer of IgG (Anhalt et al., 1982), now makes it feasible to determine whether antibodies (either from patients or raised in animals) directed against certain epitopes are associated with
increased severity of disease in humans and/or are capable of inducing disease in animals. These types of studies should lead to a more detailed
understanding of the role for this novel epithelial cadheriruin normal epidermis and in disease.
References
Amagai, M., Elgart, G.W., Klaus-Kovtun, V., and Stanley, J.R. (1991). Southern analysis of the
230-kD bullous pemphigoid gene in normal humans, animals, and patients with junctional epidermolysis bullosa. J. Invest. Dermatol. 97 , 249-253.
Amagai, M., Hashimoto, T., Tajima, S., Inokuchi, Y., Shimizu, N., Saito, M., Miki, K., and Nishikawa, T. (1990). Partial cDNA cloning of the 230-kD mouse bullous pemphigoid antigen by use of a human
monoclonal anti-basement membrane zone antibody. J. Invest. Dermatol. 95 , 252-259. Anhalt, G.J., Labib, R.S., Voorhees, J.J., Beals,
T.F., and Diaz, L.A. (1982). Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N. Engl. J. Med. 306, 1189-1196.
Beutner, E.H., Jordon, R.E., and Chorzelski, T.P. (1968). The immunopathology of pemphigus and bullous pemphigoid. J. Invest. Dermatol. 51 , 63-80. Blaschuk, O.W., Sullivan, R., David, S., and
Pouliot, Y. (1990). Identification of a cadherin cell adhesion recognition sequence. Dev. Biol. 139 , 227-229. Collins, J.E., Legan, P.K. Kenny, T.P., MacGarvie, J., Holton, J.L., and Gar
Figure imgf000031_0001
D.R. (1991). Cloning and sequence analysis of desmosomal glycoproteins 2 and 3 desmocollins): cadherin-like desmosomal adhesion molecules with heterogeneous cytoplasiic domains. J. Cell. Biol. 113 , 381-391. Cowin, P. and Garrod, D.R. (1983). Antibodies to epithelial desmosomes show wide tissue and species cross-reactivity. Nature 302 , 148-150. Cowin, P., Kapprell, H.P., Franke, W.W., Tamkun, J., and Hynes, R.O. (1986). Plakoglobin: a protein common to different kinds of intercellular adhering junctions. Cell 46, 1063-1073. Cowin, P., Mattey, D., and Garrod, D. (1984).
Identification of desmosomal surface components (desmocollins) and inhibition of desmosome formation by specific Fab'. J. Cell Sci. 70 , 41-60. Devereux, J., Haeberli, P., and Smithies, O. (1984). A comprehensive set of sequence analysis programs for the VAX. Nucleic. Acids. Res. 12 , 387-395.
Eyre, R.W. and Stanley, J.R. (1987). Human
autoantibodies against a desmosomal protein complex with a calcium-sensitive epitope are characteristic of pemphigus foliaceus patients. J. Exp. Med. 165, 1719-1724. Eyre, R.W. and Stanley, J.R. (1988). Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus
foliaceus antigen. J. Clin. Invest. 81, 807-812. Fuchs, E. and Green, H. (1981). Regulation of
terminal differentiation of cultured human
keratinocytes by vitamin A. Cell 25, 617-625.
Gallin, W.J., Sorkin, B.C., Edelman, G.M., and
Cunningham, B.A. (1987). Sequence analysis of a cDNA clone encoding the liver cell adhesion molecule, L-CAM. Proc. Natl. Acad. Sci. U. S. A. 84 ,
2808-2812.
Goodwin, L., Hill, J.E., Raynor, K., Raszi, L., Manabe, M., and Cowin, P. (1990). Desmoglein shows extensive homology to the cadherin family of cell adhesion molecules. Biochem. Biophys. Res. Commun. 173 , 1224-1230.
Gorbsky, G. and Steinberg, M.S. (1981). Isolation of the intercellular glycoproteins of desmosomes. J. Cell Biol. 90 , 243-248. Gubler, U. and Hoffman, B.J. (1983). A simple and very efficient method for generating cDNA libraries. Gene. 25 , 263-269.
Hashimoto, K., Shafran, K.M., Webber, P.S., Lazarus, G.S., and Singer, K.H. (1983). Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. J. Exp. Med. 157 , 259-272. Hashimoto, T., Ogawa, M.M., Konohana, A., and
Nishikawa, T. (1990). Detection of pemphigus
vulgaris and pemphigus foliaceus antigens by
immunoblot analysis using different antigen sources. J. Invest. Dermatol. 94 , 327-331.
Hatta, K., Nose, A., Nagafuchi, A., and Takeichi, M. (1988). Cloning and expression of cDNA encoding a neural calcium- dependent cell adhesion molecule: its identity in the cadherin gene family. J. Cell. Biol. 106, 873-881.
Jones, J.C.R., Yokoo, K.M., and Goldman, R.D.
(1986a). Further analysis of pemphigus
autoantibodies and their use in studies on the heterogeneity, structure, and function of
desmosomes. J. Cell Biol. 102 , 1109-1117. Jones, J.C.R., Yokoo, K.M., and Goldman, R.D.
(1986b). A cell surface desmosome-associated component: identification of a tissue-specific cell adhesion molecule. Proc. Natl. Acad. Sci. USA 83 , 7282-7286.
Koch, P.J., Walsh, M.J., Schmelz, M., Goldschmidt, M.D., Zimbelmann, R., and Franke, W.W. (1990).
Identification of desmoglein, a constitutive desmosomal glycoprotein, as a member of the cadherin family of cell adhesion molecules. Eur. J. Cell Biol. 53 , 1-12.
Korman, N.J., Eyre, R.W., Klaus-Kovtun, V., and Stanley, J.R. (1989). Demonstration of an
adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and pemphigus vulgaris. N. Engl. J. Med. 321 , 631-635.
Koulu, L., Kusumi, A., Steinberg, M.S., Klaus
Kovtun, V., and Stanley, J.R. (1984). Human
autoantibodies against a desmosomal core protein in pemphigus foliaceus. J. Exp. Med. 160 , 1509-1518. Kozak, M. (1987). An analysis of 5'-coding sequences from 699 vertebrate messenger RNAs. Nucleic. Acids. Res. 15, 8125-8148. Maniatis, T., Fritsch, E.F., and Sambrook, J.
(1982). Molecular Cloning. A Laboratory Manual (Cold Spring Harbor: Cold Spring Harbor).
Mechanic, S., Raynor, K., Hill, J.E., and Cowin, P. (1991). Desmocollins form a distinct subset of the cadherin family of cell adhesion molecules. Proc. Natl. Acad. Sci. USA 88 , 4476-4480.
Merlob, P., Metzker, A., Hazaz, B.A.C., Rogovin, H., and Reisner, S.H. [1986). Neonatal pemphigus
vulgaris. Pediatrics 78 , 1102-1105.
Miller, K., Mattey, D., Measures, H., Hopkins, C, and Garrod, D. (1987). Localisation of the protein and glycoprotein components of bovine nasal
epithelial desmosomes by immunoelectron microscopy. EMBO J 6, 885-889.
Miyatani, S., Shimamura, K., Hatta, M., Nagafuchi, A., Nose, A., Matsunaga, M., Hatta, K., and
Takeichi, M. (1989). Neural cadherin: role in selective cell-cell adhesion. Science. 245 , 631-635.
Morioka, S., Lazarus, G.S., and Jensen, P.J. (1987). Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. J. Invest. Dermatol. 89 , 474-477. Mueller, H. and Franke, W.W. (1983). Biochemical and immunological characterization of desmoplakins I and II, the major polypeptides of the desmosomal plaque. J. Mol. Biol. 163 , 647-671.
Mueller, S., Klaus-Kovtun, V., and Stanley, J.R.
(1989). A 230-kD basic protein is the major bullous pemphigoid antigen. J. Invest. Dermatol. 92 , 33-38. Nagafuchi, A., Shirayoshi, Y., Okazaki, K., Yasuda, K., and Takeichi, M. (1987). Transformation of cell adhesion properties by exogenously introduced
E-cadherin cDNA. Nature. 329 , 341-343. Nagafuchi, A. and Takeichi, M. (1988). Cell binding function of E-cadherin is regulated by the
cytoplasmic domain. EMBO. J. 7, 3679-3684.
Nagafuchi, A., Takeichi, M., and Tsukita, S. (1991). The 102 kd cadherin-associated protein: similarity to vinculin and posttranscriptional regulation of expression. Cell 65, 849-857.
Nilles, L.A., Parry, D.A.D., Powers, E.E., Angst, B.D., Wagner, R.M., and Green, K.J. (1991).
Structural analysis and expression of human
desmoglein: a cadherin-like component of the
desmosome. J. Cell Sci. (in press) Nose, A., Nagafuchi, A., and Takeichi, M. (1987).
Isolation of placental cadherin cDNA: identification of a novel gene family of cell-cell adhesion
molecules. EMBO. J. 6, 3655-3661. Nose, A., Tsuji, K., and Takeichi, M. (1990).
Localization of specificity determining sites in cadherin cell adhesion molecules. Cell. 61 , 147-155.
Ozawa, M., Baribault, H., and Kemler, R. (1989). The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent
proteins structurally related in different species. EMBO. J. 8, 1711-1717. Ozawa, M., Engel, J., and Kemler, R. (1990). Single amino acid substitutions in one Ca2+ binding site of uvomorv in abolish the adhesive function. Cell. 63 , 1033-1038. Ozawa, M. and Kemler, R. (1990). Correct proteolytic cleavage is required for the cell adhesive function of uvomorulin. J. Cell. Biol. 111 , 1645-1650.
Ozawa, M., Ringwald, M., and Kemler, R. (1990).
Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc. Natl. Acad. Sci. U. S. A. 87, 4246-4250. Rheinwald, J.G. and Green, H. (1975). Serial
cultivation of strains of human epidermal
keratinocytes: the formation of keratinizing
colonies from single cells. Cell 6 , 331-344. Ringwald, M., Schuh, R., Vestweber, D., Eistetter,
H., Lottspeich, F., Engel, J., Dolz, R., Jahnig, F., Epplen, J., and Mayer, S. (1987). The structure of cell adhesion molecule uvomorulin. Insights into the molecular mechanism of Ca2+-dependent cell adhesion. EMBO. J. 6, 3647-3653.
Rock, B., Labib, R.S., and Diaz, L.A. (1990).
Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J. Clin. Invest. 85, 296-299. Roscoe, J.T., Diaz, L., Sampaio, S.A., Castro, R.M., Labib, R.S., Takahashi, Y., Patel, H., and Anhalt, G.J. (1985). Brazilian pemphigus foliaceus
autoantibodies are pathogenic to BALB/c mice by passive transfer. J. Invest. Dermatol. 85, 538-541.
Sabolinski, M.L., Beutner, E.H., Krasny, S., Kumar, V., Huang, J., Chorzelski, T.P., Sampaio, S., and Bystryn, J.C. (1987). Substrate specificity of anti-epithelial antibodies of pemphigus vulgaris and pemphigus foliaceus sera in immunofluorescence tests on monkey and guinea pig esophagus substrates. J. Invest. Dermatol. 88 , 545-549.
Sams, W.M.Jr. and Gammon, W.R. (1982). Mechanism of lesion production in pemphigus and pemphigoid. J. Am. Acad. Dermatol. 6, 431-452.
Sams, W.M.Jr. and Jordon, R.E. (1971). Correlation of pemphigoid and pemphigus antibody titres with activity of disease. Br. J. Dermatol. 84 , 7-13.
Schiltz, J.R. and Michel, B. (1976). Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J. Invest. Dermatol. 67, 254-260. Schmelz, M., Duden, R., Cowin, P., and Franke, W.W. (1986). A constitutive transmembrane glycoprotein of Mr 165000 (desmoglein) in epidermal and
non-epidermal desmosomes. I. Biochemical
identification of the polypeptide. Eur. J. Cell Biol. 42, 177-183.
Shimoyama, Y., Yoshida, T., Terada, M., Shimosato, Y., Abe, O., and Hirohashi, S. (1989). Molecular cloning of a human Ca2+-dependent cell-cell adhesion molecule homologous to mouse placental cadherin: its low expression in human placental tissues. J. Cell. Biol. 109 , 1787-1794. Shirayoshi, Y., Hatta, K., Hosoda, M., Tsunasawa,
S., Sakiyama, F., and Takeichi, M. (1986). Cadherin cell adhesion molecules with distinct binding specificities share a common structure. EMBO. J. 5, 2485-2488.
Stanley, J.R. (1989). Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J. Clin. Invest. 83 , 1443-1448. Stanley, J.R., Alvarez, O.M., Bere, E.W.Jr.,
Eaglstein, W.H., and Katz, S.I. (1981). Detection of basement membrane zone antigens during epidermal wound healing in pigs. J. Invest. Dermatol. 77 , 240-243.
Stanley, J.R., Koulu, L., and Thivolet, C. (1984). Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus
autoantibodies. J. Clin. Invest. 74 , 313-320. Stanley, J.R., Koulu, L., Klaus Kovtun, V., and Steinberg, M.S. (1986). A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J. Immunol. 136, 1227-1230.
Stanley, J.R., Tanaka, T., Mueller, S.,
Klaus-Kovtun, V., and Roop, D. (1988). Isolation of cDNA for bullous pemphigoid antigen by use of patients' autoantibodies. J. Clin. Invest. 82 ,
1864-1870.
Stanley, J.R., Woodley, D.T., and Katz, S.I. (1984). Identification and partial characterization of pemphigoid antigen extracted from normal human skin. J. Invest. Dermatol. 82 , 108-111.
Stanley, J.R., Yaar, M., Hawley Nelson, P., and Katz, S.I. (1982). Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J. Clin. Invest. 70 , 281-288.
Stanley, J.R. and Yuspa, S.H. (1983). Specific epidermal protein markers are modulated during calcium-induced terminal differentiation. J. Cell Biol. 96, 1809-1814.
Steinberg, M.S., Shida, H., Giudice, G.J., Shida, M., Patel, N.H., and Blaschuk, O.W. (1987). On the molecular organization, diversity and functions of desmosomal proteins. Ciba. Found. Symp. 125, 3-25.
Takeichi, M. (1990). Cadherins: a molecular family important in selective cell-cell adhesion. Annu.
Rev. Biochem. 59, 237-252. Takeichi, M. (1991). Cadherin cell adhesion
receptors as a morphogenetic regulator. Science. 251 , 1451-1455.
Tanaka, T., Korman, N.J., Shimizu, H., Eady, R.A.J., Klaus-Kovtun, V., Cehrs, K., and Stanley, J.R.
(1990). Production of rabbit antibodies against carboxy-terminal epitopes encoded by bullous
pemphigoid cDNA. J. Invest. Dermatol. 94 , 617-623.
Towbin, H., Staehelin, T., and Gordon, J. (1979). Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose sheets:
procedure and some applications. Proc. Natl. Acad. Sci. USA 76, 4350-4354.
Walsh, F.S., Barton, C.H., Putt, W., Moore, S.E., Resell, D., Spurr, N., and Goodfellow, P.N. (1990). The N-cadherin gene maps to human chromosome 18 and is not linked to the E-cadherin gene. J. Neurochem. 55 , 805-812.
Wheeler, G.N., Parker, A.E., Thomas, C.L.,
Ataliotis, P., Poynter, D., Arnemann, J., Rutman,
A.J., Pidsley, S.C., Watt, F.M., Rees, D.A., Buxton, R.S., and Magee, A.I. (1991). Desmosomal
glycoprotein DGI, a component of intercellular desmosome junctions, is related to the cadherin family of cell adhesion molecules. Proc. Natl. Acad. Sci. USA 88 , 4796-4800.
Wolff, K. and Schreiner, E. (1971). Ultrastructural localization of pemphigus auto-antibodies within the epidermis. Nature 229 , 59-60. Young, R.A. and Davis, R.W. (1983). Efficient isolation of genes by using antibody probes. Proc. Natl. Acad. Sci. USA 80 , 1194-1198.

Claims

CLAIMS: 1. A DNA fragment that encodes pemphigus
vulgaris antigen.
2. The DNA fragment according to claim 1,
wherein said fragment has the sequence:
10 20 30 40 50 60 | | | | | | 1 TTTTCTTAGA CATTAACTGC AGACGGCTGG CAGGATAGAA GCAGCGGCTC ACTTGGACTT
AAAAGAATCT GTAATTGACG TCTGCCGACC GTCCTATCTT CGTCGCCGAG TGAACCTGAA
61 TTTCACCAGG GAAATCAGAG ACAATGATGG GGCTCTTCCC CAGAACTACA GGGGCTCTGG AAAGTGGTCC CTTTAGTCTC TGTTACTACC CCGAGAAGGG GTCTTGATGT CCCCGAGACC
1 21 CCATCTTCGT GGTGGTCATA T TGGTTCATG GAGAATTGCG AATAGAGACT AAAGGTCAAT GGTAGAAGCA CCACCAGTAT AA CCAAGTAC CTCTTAACGC TTATCTCTGA TTTCCAGTTA
1 8 1 ATGATGAAGA AGAGATGACT ATGCAACAAG CTAAAAGAAG GCAAAAACGT GAATGGGTGA TACTACTTCT TCTCTACTGA TACGTTGTTC GATTTTCTTC CGTTTTTGCA CTTACCCACT
241 AATTTGCCAA ACCCTGCAGA GAAGGAGAAG ATAACTCAAA AAGAAACCCA ATTGCCAAGA TTAAACGGTT TGGGACGTCT CTTCCTCTTC TATTGAGTTT TTCTTTGGGT TAACGGTTCT
301 TTACTTCAGA TTACCAAGCA ACCCAGAAAA TCACCTACCG AATCTCTGGA GTGGGAATCG AATGAAGTCT AATGGTTCGT TGGGTCTTTT AGTGGATGGC TTAGAGACCT CACCCTTAGC
361 ATCAGCCGCC TTTTGGAATC TTTGTTGTTG ACAAAAACAC TGGAGATATT AACATAACAG TAGTCGGCGG AAAACCTTAG AAACAACAAC TGTTTTTGTG ACCTCTATAA TTGTATTGTC
421 CTATAGTCGA CCGGGAGGAA ACTCCAAGCT TCCTGATCAC ATGTCGGGCT CTAAATGCCC GATATCAGCT GGCCCTCCTT TGAGGTTCGA AGGACTAGTG TACAGCCCGA GATTTACGGG
48 1 AAGGACTAGA TGTAGAGAAA CCACTTATAC TAACGGTTAA AATTTTGGAT ATTAATGATA TTCCTGATCT ACATCTCTTT GGTGAATATG ATTGCCAATT TTAAAACCTA TAATTACTAT
541 ATCCTCCAGT ATTTTCACAA CAAATTTTCA TGGGTGAAAT TGAAGAAAAT AGTGCCTCAA TAGGAGGTCA TAAAAGTGTT GTTTAAAAGT ACCCACTTTA ACTTCTTTTA TCACGGAGTT
601 ACTCACTGGT GATGATACTA AATGCCACAG ATCAGATGA ACCAAACCAC TTGAATTCTA TGAGTGACCA CTACTATGAT TTACGGTGTC TACTCTACT TGGTTTGGTG AACTTAAGAT
661 AAATTGCCTT CAAAATTGTC TCTCAGGAAC CAGCAGGCAC ACCCATGTTC CTCCTAAGCA TTTAACGGAA GTTTTAACAG AGAGTCCTTG GTCGTCCGTG TGGGTACAAG GAGGATTCGT
721 GAAACACTGG GGAAGTCCGT ACTTTGACCA ATTCTCTTGA CCGAGAGCAA GCTAGCAGCT CTTTGTGACC CCTTCAGGCA TGAAACTGGT TAAGAGAACT GGCTCTCGTT CGATCGTCGA
78 1 ATCGTCTGGT TGTGAGTGGT GCAGACAAAG ATGGAGAAGG ACTATCAACT CAATGTGAAT TAGCAGACCA ACACTCACCA CGTCTGTTTC TACCTCTTCC TGATAGTTGA GTTACACTTA
841 GTAATATTAA AGTGAAAGAT GTCAACGATA ACTTCCCAAT GTTTAGAGAC TCTCAGTATT CATTATAATT TCACTTTCTA CAGTTGCTAT TGAAGGGTTA CAAATCTCTG AGAGTCATAA
901 CAGCACGTAT TGAAGAAAAT ATTTTAAGTT CTGAATTACT TCGATTTCAA GTAACAGATT CTCGTGCATA ACTTCTTTTA TAAAATTCAA GACTTAATGA AGCTAAAGTT CATTGTCTAA 961 TGGATGAAGA GTACACAGAT AATTGGCTTG CAGTATATTT CTTTACCTCT GGGAATGAAG ACCTACTTCT CATGTGTCTA TTAACCGAAC GTCATATAAA GAAATGGAGA CCCTTACTTC 1021 GAAATTGGTT TGAAATACAA ACTGATCCTA GAACTAATGA AGGCATCCTG AAAGTGGTGA CTTTAACCAA ACTTTATGTT TGACTAGGAT CTTGATTACT TCCGTAGGAC TTTCACCACT
1081 AGGCTCTAGA TTATGAACAA CTACAAAGGG TGAAACTTAG TATTGCTGTC AAAAACAAAG TCCCGAGATCT AATACTTGTT GATGTTTGGC ACTTTGAATC ATAACGACAG TTTTTGTTTC
1141 CTGAATTTCA CCAATCAGTT ATCTCTCGAT ACCGAGTTCA GTCAACCCCA GTCACAATTC GACTTAAAGT GGTTAGTCAA TAGAGAGCTA TGGCTCAAGT CAGTTGGGGT CAGTGTTAAG
1201 AGGTAATAAA TGTAAGAGAA GGAATTGCAT TCCGTCCTGC TTCCAAGACA TTTACTGTGC TCCATTATTT ACATTCTCTT CCTTAACGTA AGGCAGGACG AAGGTTCTGT AAATGACACG
1261 AAAAAGGCAT AAGTAGCAAA AAATTGGTGG ATTATATCCT GGGAACATAT CAAGCCATCG TTTTTCCGTA TTCATCGTTT TTTAACCACC TAATATAGGA CCCTTGTATA GTTCGGTAGC
1321 ATGAGGACAC TAACAAAGCT GCCTCAAATG TCAAATATGT CATGGGACGT AACGATGGTG TACTCCTGTG ATTGTTTCGA CGGAGTTTAC AGTTTATACA GTACCCTGCA TTGCTACCAC
1381 GATACCTAAT GATTGATTCA AAAACTCCTG AAATCAAATT TGTCAAAAAT ATGAACCGAG CTATGGATTA CTAACTAAGT TTTTGACGAC TTTAGTTTAA ACAGTTTTTA TACTTGGCTC
1441 ATTCTACTTT CATAGTTAAC AAAACAATCA CAGCTGAGGT TCTGGCCATA GATGAATACA TAAGATGAAA GTATCAATTG TTTTGTTAGT GTCGACTCCA AGACCGGTAT CTACTTATGT
1 561 CAACAGCTGT CCTCGAAAAA GATGCAGTTT GCAGTTCTTC ACCTTCCGTG GTTGTCTCCG GTTGTCGACA GGAGCTTTTT CTACGTCAAA CGTCAAGAAG TGGAAGGCAC CAACAGAGGC
1621 CTAGAACACT GAATAATAGA TACACTGGCC CCTATACATT TGCACTGGAA GATCAACCTG GATCTTGTGA CTTATTATCT ATGTGACCGG GGATATGTAA ACGTGACCTT CTAGTTGGAC
1681 TAAAGTTGCC TGCCGTATGG AGTATCACAA CCCTCAATGC TACCTCGGCC CTCCTCAGAG ATTTCAACGG ACGGCATACC TCATAGTGTT GGGAGTTACG ATGGAGCCGG GAGGAGTCTC
1741 CCCAGGAACA GATACCTCCT GGAGTATACC ACATCTCCCT GGTACTTACA GACAGTCAGA
GGGTCCTTGT CTATGGAGGA CCTCATATGG TGTAGAGGGA CCATGAATGT CTGTCAGTC T
1801 ACAATCGGTC TGAGATGCCA CGCAGCTTGA CACTGGAAGT CTGTCAGTGT GACAACAGGG TGTTAGCCAC ACTCTACGGT GCCTCGAACT GTGACCTTCA GACAGTCACA CTGTTGTCCC
1861 GCATCTGTGG AACTTCTTAC CCAACCACAA GCCCTGGGAC CAGGTATGGC AGGCCGCACT CGTAGACACC TTGAAGAATG GGTTGGTGTT CGGGACCCTG GTCCATACCG TCCGGCGTG A
1921 CAGGGAGGCT GGGGCCTGCC GCCATCGGCC TGCTGCTCCT TGGTCTCCTG CTGCTGCTGT GTCCCTCCGA CCCCGGACGG CGGTAGCCGG ACGACGAGGA ACCAGAGCAC GACGACGACA
1981 TGGCCCCCCT TCTGCTGTTG ACCTGTGACT GTGGGGCAGG TTCTACTGGG GGAGTGACAG ACCGGGGGGA AGACGACAAC TGGACACTGA CACCCCGTCC AAGATGACCC CCTCACTGTC 2041 GTGGTTTTAT CCCAGTTCCT GATGGCTCAG AAGGAACAAT TCATCAGTGG GGAATTGAAG CACCAAAATA GGGTCAAGGA CTACCGAGTC TTCCTTGTTA AGTAGTCACC CCTTAACTTC
2101 GAGCCCATCC TGAAGACAAG GAAATCACAA ATATTTGTGT GCCTCCTGTA ACAGCCAATG CTCGGGTAGG ACTTCTGTTC CTTTAGTGTT TATAAACACA CGGAGGACAT TGTCGGTTAC
2161 GAGCCGATTT CATGGAAAGT TCTGAAGTTT GTACAAATAC GTATGCCAGA GGCACAGCGG CTCGGCTAAA GTACCTTTCA AGACTTCAAA CATGTTTATG CATACGGTCT CCGTGTCGCC
2221 TGGAAGGCAC TTCAGGAATG GAAATGACCA CTAAGCTTGG AGCAGCCACT GAATCTGGAG ACCTTCCGTG AAGTCCTTAC CTTTACTGGT GATTCGAACC TCGTCGGTGA CTTAGACCTC
2281 GTGCTGCAGG CTTTGCAACA GGGACAGTGT CAGGAGCTGC TTCAGGATTC GGAGCAGCCA CACGACGTCC GAAACGTTGT CCCTGTCACA GTCCTCGACG AAGTCCTAAG CCTCGTCGGT
2341 CTGGAGTTGG CATCTGTTCC TCAGGGCAGT CTGGAACCAT GAGAACAAGG CATTCCACTG GACCTCAACC GTAGACAAGG AGTCCCGTCA GACCTTGGTA CTCTTGTTCC GTAAGGTGA C
2401 GAGGAACCAA TAAGGACTAC GCTGATGGGG CGATAAGCAT GAATTTTCTG GACTCCTACT CTCCTTGGTT ATTCCTGATG CGACTACCCC GCTATTCGTA CTTAAAAGAC CTGAGGATGA
2461 TTTCTCAGAA AGCATTTGCC TGTGCGGAGG AAGACGATGG CCAGGAAGCA AATGACTGCT AAAGAGTCTT TCGTAAACGG ACACGCCTCC TTCTGCTACC GGTCCTTCGT TTACTGACGA
2521 TGTTGATCTA TGATAATGAA GGCGCAGATG CCACTGGTTC TCCTGTGGGC TCCGTGGGTT ACAACTAGAT ACTATTACTT CCGCGTCTAC GGTGACCAAG AGGACACCCG AGGCACCCAA
2581 GTTGCAGTTT TATTGCTGAT GACCTGGATG ACAGCTTCTT GGACTCACTT GGACCCAAAT CAACGTCAAA ATAACGACTA CTGGACCTAC TGTCGAAGAA CCTGAGTGAA CCTGGGTTTA
2641 TTAAAAAACT TGCAGAGATA AGCCTTGGTG TTGATGGTGA AGGCAAAGAA GTTCAGCCAC AATTTTTTGA ACGTCTCTAT TCGGAACCAC AACTACCACT TCCGTTTCTT CAAGTCGGTG
2701 CCTCTAAAGA CAGCGGTTAT GGGATTGAAT CCTGTGGCCA TCCCATAGAA GTCCAGCAGA GGAGATTTCT GTCGCCAATA CCCTAACTTA GGACACCGGT AGGGTATCTT CAGGTCGTCT
2761 CAGGATTTGT TAAGTGCCAG ACTTTGTCAG GAAGTCAAGG AGCTTCTGCT TTGTCCGCCT GTCCTAAACA ATTCACGGTC TGAAACAG1 C CTTCAGTTCC TCGAAGACGA AACAGGCGGA
2821 CTGGGTCTGT CCAGCCAGCT GTTTCCATCC CTGACCCTCT GCAGCATGGT AACTATTTAG GACCCAGACA GGTCGGTCGA CAAAGGTAGG GACTGGGAGA CGTCGTACCA TTGATAAATC
2881 TAACGGAGAC TTACTCGGCT TCTGGTTCCC TCGTGCAACC TTCCACTGCA GGCTTTGATC ATTGCCTCTG AATGAGCCGA AGACCAAGGG AGCACGTTGG AAGGTGACGT CCGAAACTAG
2941 CACTTCTCAC ACAAAATGTG ATAGTGACAG AAAGGGTGAT CTGTCCCATT TCCAGTGTTC GTGAAGAGTG TGTTTTACAC TATCACTGTC TTTCCCACTA GACAGGGTAA AGGTCACAAG
3001 CTGGCAACCT AGCTGGCCCA ACGCAGCTAC GAGGGTCACA TACTATGCTC TGTACAGAGG GACCGTTGGA TCGACCGGGT TGCGTCGATG CTCCCAGTGT ATGATACGAG ACATGTCTCC
3061 ATCCTTGCTC CCGTCTAATA TGACCAGAAT GAGCTGGAAT ACCACACTGA CCAAATCTGG TAGGAACGAG GGCAGATTAT ACTGGTCTTA CTCGACCTTA TGGTGTGACT GGTTTAGACC
3121 ATCTTTGGAC TAAAGTATTC AAAATAGCAT AGCAAAGCTC ACTGTATTGG GCTAATAATT TAGAAACCTG ATTTCATAAG TTTTATCGTA TCGTTTCGAG TGACATAACC CGATTATTAA
3181 TGGCACTTAT TAGCTTCTCT CATAAACTGA TCACGATTAT AAATTAAATG TTTGGGTTCA ACCGTGAATA ATCGAAGAGA GTATTTGACT AGTGCTAATA TTTAATTTAC AAACCCAAGT
3241 TACCCCAAAA GCAATATGTT GTCACTCCTA ATTCTCAAGT ACTATTCAAA TTGTAGTAAA ATGGGGTTTT CGTTATACAA CAGTGAGGAT TAAGAGTTCA TGATAAGTTT AACATCATTT
3301 TCTTAAAGTT TTTCAAAACC CTAAAATCAT ATTCGC
AGAATTTCAA AAAGTTTTGG GATTTTAGTA TAAGCG
3. The DNA fragment according to claim 2 wherein said DNA fragment encodes the amino acid
sequence:
5 10 15 20 25 30
| | | | | | 1 K M G L F P R T T G A L A I F V V V I L V H G E L R I E T K 31 G Q Y D E E E M T M Q Q A K R R Q K R E W V K F A K P C R E 61 G E D N S K R N P I A K I T S D Y Q A T Q K I T Y R I S G V 91 G I d Q P P F G I F V V D K N T G D I N I T A I V D R E E T 121 P S F L I T C R A L N A Q G L D V E K P L I L T V K I L D I151 N D N P P V F S Q Q I F M G E I E E N S A S N S L V K I L N 181 A T D A D E P N H L N S K I A F K I V S Q E P A G T P M E L211 L S R N T G E V R T L T N S L O R E Q A S S Y R L V V S G A241 D K D G E G L S T Q C E C N I K V K D V N D N F P M F R D S271 Q Y S A R I E E N I L S S E L L R F Q V T D L D E E Y T D N 301 W L A V Y F F T S G N E G N W F E I Q T D P R T N E G I L K 331 V V K A L D Y E Q L Q S V K L S I A V K N K A E F H Q S V I361 S R Y R V Q S T P V T I Q V I N V R E G I A F R P A S K T F 391 T V Q K G I S S K K L V D Y I L G T Y Q A I D F D T N K A A 421 S N V K Y V M G R N D G G Y L M I D S K T A E I K F V K N M451 N R D S T F I V N K T I T A E V L A I D E Y T G K T S T G T481 V Y V R V P D F N D N C P T A V L E K D A V C S S S P S V V511 V S A R T L N N R Y T G P Y T F A L E D Q P V K L P A V W S541 I T T L N A T S A L L R A Q E Q I P P G V Y H I S L V L T D571 S Q N N R C E M P R S L T L E V C Q C D N R G I C G T S Y P601 T T S P G T R Y G R P H S G R L G P A A I G L L L L G L L L631 L L L A P L L L L T C D C G A G S T G G V T G G F I P V P D661 G S E G T I H Q W G I E G A H P E D K E I T N I C V P P V T691 A N G A D F M E S S E V C T N T Y A R G T A V E G T S G M E721 M T T K L G A A T E S G G A A G F A T G T V S G A A S G F G751 A A T G V G I C S S G Q S G T M R T R H S T G G T N K D Y A781 D G A I S M N F L D S Y F S Q K A F A C A E E D D G Q E A N 811 D C L L I Y D N E G A D A T G S P V G S V G C C S F I A D D 841 L D D S F L D S L G P K F K K L A E I S L G V D G E G K E V871 Q P P S K D S G Y G I E S C G H P I E V Q Q T G F V K C Q T901 L S G S Q G A S A L S A S G S V Q P A V S I P D P L Q H G N931 Y L V T E T Y S A S G S L V Q P S T A G F D P L L T Q N V I961 V T E R V I C P I S S V P G N L A G P T Q L R G S H T M L C991 T E D P C S R L I
4. A DNA fragment according to claim 3, comprising at least 12 bases of the sequence set forth therein.
5. A recombinant DNA construct comprising:
(i) a vector, and
(ii) said DNA fragment according to claim 1.
6. A recombinant DNA construct comprising:
(i) a vector, and
(ii) said DNA fragment according to claim 2.
7. The recombinant DNA construct
according to claim 5, wherein said vector is a eukaryotic expression vector.
8. The recombinant DNA construct according to claim 6, wherein said vector is a eukaryotic expression vector.
9. The recombinant DNA construct
according to claim 5, wherein said DNA fragment
encodes the amino acid sequence:
5 10 15 20 25 30 | | | | | |
1 M M G L F P R T T G A L A I F V V V I L V H G E L R I E T K
31 G Q Y D E E E M T M Q Q A K R R Q K R E W V K F A K P C R E
61 G E D N S K R N P I A K I T S D Y Q A T Q K I T Y R I S G V
91 G I D Q P P F G I F V V D K N T G D I N I T A I V D R E E T
121 P S F L I T C R A L H A Q G L D V E K P L I L T V K I L D I
151 K D N P P V F S Q Q I F M G E I E E H S A S N S L V M I L N
181 A T D A D E P N H L N S K I A F K I V S Q E P A G T P M F L
211 L S R N T G E V R T L T N S L D R E Q A S S Y R L V V S G A
241 D K D G E G L S T Q C E C N I K V K D V N D H F P M F RD S
271 Q Y S A R I E E N I L S S E L L R F Q V T D L D E E Y T D N
301 W L A V Y F F T S G N E G N W F E Q T D P R T N E G I L K
331 V V K A L D Y E Q L Q S V K L S I V K N K A E F H Q S V I
361 S R Y R V Q S T P V T I Q V I N V
Figure imgf000049_0001
E G I A F R P A S K T F
391 T V Q K G I S S K K L V D Y I L G T Y Q A I D E D T N K A A
421 S N V K Y V M G R N D G G Y L M I D S K T A E I K F V K N M 451 N R D S T F X V N K T I T A E V L A I D E Y T G X T S T G T 481 V Y V R V P D F N D N C P T A V L E K D A V C S S S P S V V 511 V S A R T V V N R Y T G P Y T F A L E D Q P V K L P A V W S 541 I T T L N A T S A L L R A Q S Q I P P G V Y H I S L V L T D 571 S Q N N R C E M P R S L T L E V C Q C D N R G I C G T S Y P 601 T T S P G T R Y G R P H S G R L G P A A I G L L L L G L L L 631 L L L A P L L L L T C D C G A G S T G G V T G G F I P V P D 661 G S E G T I E Q H G I E G A H P E D K E I T N I C V P P V T 691 A N G A D F K E S S E V C T N T Y A R G T A V E G T S G M E721 M T T K L G A A T E S G G A A G F A T G T V S G A A S G F G751 A A T G V G I C S S G Q S G T M R T R H S T G G T N K D Y A781 0 G A I S K S F L D S Y F S Q K A F A C A E E D D G Q E A N811 D C L L I Y C S E G A D A A G S P V G S V G C C S F I A D D841 L D D S F L C S L G P K F K K L A E I S L G V D G E G K E V871 Q P P S K D S G Y G I E S C G H P I E V Q Q T G F V K C Q T901 L S G S Q G A S A L S A S G S V Q P A V S I P D P L Q H G N931 Y L V T E T E S A S G S L V Q P S T A G F D P L L T Q N V I961 V T E R V I C P I S S V P G N L A G P T Q L R G S H T M L C991 T E D P C S E L I
10. The recombinant DNA construct
according to claim 6, wherein said DNA fragment
encodes the amino acid sequence:
5 10 15 20 25 30 | | | | | | 1 K M G L F P R T T G A L A I F V V V I L V H G E L R I E T K 31 G Q Y D E E E M T M Q Q A K R R Q K R E W V K F A K P C R E 61 G E D N S K R N P I A K I T S D Y Q A T Q K I T Y R I S G V 91 G I D Q P P F G I F V V D K N T G D I N I T A I V D R E E T 121 P S F L I T C R A L N A Q G L D V E K P L I L T V X I L D I 15 1 N D N P P V F S Q Q I F M G E I E E N S A S N S L V M I L N 18 1 A T D A D E P N H L N S K I A F K I V S Q E P A G T P M F L 21 1 L S R N T G E V R T L T N S L D R E Q A S S Y R L V V S G A 241 D K D G E G L S T Q C E C N I K V K D V N D N F P H F R D S 271 Q Y S A R I E E N I L S S E L L R F Q V T D L D E E Y T D N 301 W L A V Y F F T S G N E G N W F E I Q T D P R T N E G I L X 33 1 V V K A L D Y E Q L Q S V K L S I A V K N K A E F H Q S V I 361 S R Y R V Q S T P V T I Q V I N V R E G I A F R P A S X T F 391 T V Q K G I S S K K L V D Y I L G T Y Q A I D E D T N X A A 421 S N V K Y V M G R N D G G Y L M I D S K T A E I X F V X N M45 1 K R D S T F I V N K T I T A E V L A I D E Y T G X T S T G T 481 V Y V R V P D F N D N C P T A V L E K D A V C S S S P S V V 511 V S A R T L N N R Y T G P Y T F A L E D Q P V X L P A V K S541 I T T L N A T S A L L R A Q E Q I P P G V Y H I S L V L T D571 S Q N N R C E M P R S L T L E V C Q C D N R G I C G T S Y P601 T T S P G T R Y G R P H S G R L G P A A I G L L L L G L L L 63 1 L L L A P L L L L T C D C G A G S T G G V T G G F I P V P D 661 G S E G T I H Q N G I E G A H P E D K E I T N I C V P P V T 691 A N G A D F M E S S E V C T N T Y A R G T A V E G T S G H E 721 H T T K L G A A T E S G G A A G F A T G T V S G A A S G F G75 1 A A T G V G I C S S G Q S G T M R T R H S T G G T N X D Y A78 1 D G A I S M N F L D S Y F S Q K A F A C A E E D D G Q E A N8 1 1 D C L L I Y D N E G A D A T G S P V G S V G C C S F I A D D841 L D D S F L D S L G P K F K K L A E I S L G V D G E G K E V871 Q P P S K D S G Y G I E S C G H P I E V Q Q T G P V K C Q T 901 L S G S Q G A S A L S A S G S V Q P A V S I P D P L Q H G N93 1 Y L V T E T Y S A S G S L V Q P S T A G F D P L L T Q H V I 961 V T E R V I C P I S S V P G N L A G P T Q L R G S H T M L C991 T E D P C S R L I
11. A host cell transformed with the recombinant DNA construct according to claim 5.
12. A host cell transformed with the recombinant DNA construct according to claim 6.
13. The host cell according to claim 11, wherein said cell is a eukaryotic cell.
14. The host cell according to claim 12, wherein said cell is a eukaryotic cell.
15. A method of producing pemphigus vulgaris antigen which comprises culturing the cell according to claim 11, under conditions such that said DNA fragment is expressed and said pemphigus vulgaris antigen is thereby produced, and isolating said pemphigus vulgaris antigen.
16. A method of producing pemphigus vulgaris antigen which comprises culturing the cell according to claim 12, under conditions such that said DNA fragment is expressed and said pemphigus vulgaris antigen is thereby produced, and isolating said pemphigus vulgaris antigen.
17. The protein or glycoprotein pemphigus vulgaris antigen expressed by the DNA fragment of
claim 2 having the amino acid sequence:
5 10 15 20 25 30
| | | | | | 1 M K G L F P R T T G A L A I F V V V I L V H G E l R I E T K 31 G Q Y D E E E H T K Q Q A K R R Q K R E W V K F A K P C R E 61 G E D N S K R M P I A K I T S D Y Q A T Q K I T Y R I S G V 91 G I D Q P P F G I F V V D X N T G D I N I T A I V D R E E T 121 P S F L I T C R A L N A Q G L D V E K P L I L T V K I L D I 151 H D N P P V F S Q Q I F K G E I E E N S A S N S L V M I L N 181 A T D A D E P N H L N S K I A F K I V S Q E P A G T P M F L 211 L S R N T G E V R T L T N S L D R E Q A S S Y R L V V S G A 244 D K D G E G L S T Q C E C N I K V X D V N D N F P M F R D S 271 Q Y S A R I E E N Z L S S E L L R F Q V T D L D E E Y T D N 301 W L A V Y F F T S G N E G N H F E I Q T D P R T N E G I L K 3 31 V V K A L D Y E Q L Q S V K L S I A V K N K A E F H Q S V I 361 S R Y R V Q S T P V T I Q V Z N V R E G I A F R P A S K T F 391 T V Q K G I S S K X L V D Y I L G T Y Q A I D E D T N K A A 442 S N V K Y V M G R N D G G Y L M I D S K T A E I K F V K N M 451 N R D S T F I V H K T I T A E V L A I D E Y T G K T S T G T 481 V Y V R V P D F N D N C P T A V L E K D A V C S S S P S V V 511 V S A R T L N N R Y T G P Y T F A L E D Q P V X L P A V W S 541 I T T L N A T S A L L R A Q E Q I P P G V Y H I S L V L T D 571 S Q N N R C E M P R S L T L E V C Q C D N R G I C G T S Y P 601 T T S P G T R Y G R P H S G R L G P A A I G L L L L G L L L 631 L L L A P L L L L T C D C G A G S T G G V T G G F I P V P D661 G S E G T I H Q W G I E G A H P E D K E I T N I C V P P V T691 A N G A D F M E S S E V C T N T Y A R G T A V E G T S G M E721 M T T K L G A A T E S G G A A G F A T G T V S G A A S G F G751 A A T G V G I C S S G Q S G T M R T R H S T G G T N K D Y A781 O G A I S M N F L D S Y F S Q K A F A C A E E D D G Q E A N811 D C L L I Y D N E G A D A T G S P V G S V G C C S F I A D D 841 L D D S F L D S L G P X F K K L A E I S L G V D G E G K E V871 Q P P S K D S G Y G I E S C G H P I E V Q Q T G F V K C Q T901 L S G S Q G A S A L S A S G S V Q P A V S I P D P L Q H G N931 Y L V T E T Y S A S G S L V Q P S T A G F D P L L T Q N V I961 V T E R V I C P I S S V P G N L A G P T Q L R G S H T M L C991 T E D P C S R L I
18. An antibody to the peptide having the amino acid sequence:
5 10 15 20 25 30
| | | | | | 1 M K G L F P R T T G A L A I F V V V I L V H G E l R I E T K 31 G Q Y D E E E H T K Q Q A K R R Q K R E W V K F A K P C R E 61 G E D N S K R M P I A K I T S D Y Q A T Q K I T Y R I S G V 91 G I D Q P P F G I F V V D X N T G D I N I T A I V D R E E T 121 P S F L I T C R A L N A Q G L D V E K P L I L T V K I L D I 151 H D N P P V F S Q Q I F K G E I E E N S A S N S L V M I L N 181 A T D A D E P N H L N S K I A F K I V S Q E P A G T P M F L 211 L S R N T G E V R T L T N S L D R E Q A S S Y R L V V S G A 244 D K D G E G L S T Q C E C N I K V X D V N D N F P M F R D S 271 Q Y S A R I E E N Z L S S E L L R F Q V T D L D E E Y T D N 301 W L A V Y F F T S G N E G N H F E I Q T D P R T N E G I L K 3 31 V V K A L D Y E Q L Q S V K L S I A V K N K A E F H Q S V I 361 S R Y R V Q S T P V T I Q V Z N V R E G I A F R P A S K T F 391 T V Q K G I S S K X L V D Y I L G T Y Q A I D E D T N K A A 442 S N V K Y V M G R N D G G Y L M I D S K T A E I K F V K N M 451 N R D S T F I V H K T I T A E V L A I D E Y T G K T S T G T 481 V Y V R V P D F N D N C P T A V L E K D A V C S S S P S V V 511 V S A R T L N N R Y T G P Y T F A L E D Q P V X L P A V W S 541 I T T L N A T S A L L R A Q E Q I P P G V Y H I S L V L T D 571 S Q N N R C E M P R S L T L E V C Q C D N R G I C G T S Y P 601 T T S P G T R Y G R P H S G R L G P A A I G L L L L G L L L 631 L L L A P L L L L T C D C G A G S T G G V T G G F I P V P D661 G S E G T I H Q W G I E G A H P E D K E I T N I C V P P V T691 A N G A D F M E S S E V C T N T Y A R G T A V E G T S G M E721 M T T K L G A A T E S G G A A G F A T G T V S G A A S G F G751 A A T G V G I C S S G Q S G T M R T R H S T G G T N K D Y A781 O G A I S M N F L D S Y F S Q K A F A C A E E D D G Q E A N811 D C L L I Y D N E G A D A T G S P V G S V G C C S F I A D D 841 L D D S F L D S L G P X F K K L A E I S L G V D G E G K E V871 Q P P S K D S G Y G I E S C G H P I E V Q Q T G F V K C Q T901 L S G S Q G A S A L S A S G S V Q P A V S I P D P L Q H G N931 Y L V T E T Y S A S G S L V Q P S T A G F D P L L T Q N V I961 V T E R V I C P I S S V P G N L A G P T Q L R G S H T M L C991 T E D P C S R L I
19. A method for the diagnosis of pemphigus vulgaris disease comprising the steps of:
(i) coating a surface with all, or a unique portion, of the pemphigus vulgaris antigen according to claim 17;
(ii) contacting said coated surface with serum from an individual suspected of having said disease; and
(iii) detecting the presence or absence of a complex formed between said pemphigus vulgaris antigen and antibodies specific therefor present in said serum.
20. A diagnostic kit comprising a recombinantly produced pemphigus vulgaris antigen and ancillary reagents suitable for use in detecting the presence of antibodies to said pemphigus
vulgaris antigen in a mammalian serum or tissue sample.
21. A therapeutic method for the treatment of pemphigus vulgaris disease comprising performing plasmapheresis on an individual having pemphigus vulgaris disease, wherein the pemphigus vulgaris antigen according to claim 17 is contacted with the individual's blood prior to reinfusion of the blood into the individual.
PCT/US1992/009933 1991-11-27 1992-11-24 Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use WO1993010813A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79891891A 1991-11-27 1991-11-27
US798,918 1991-11-27

Publications (1)

Publication Number Publication Date
WO1993010813A1 true WO1993010813A1 (en) 1993-06-10

Family

ID=25174591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009933 WO1993010813A1 (en) 1991-11-27 1992-11-24 Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use

Country Status (2)

Country Link
AU (1) AU3178393A (en)
WO (1) WO1993010813A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759771A4 (en) * 1995-03-07 1999-12-29 Harvard College IDENTIFICATION OF SELF-ANTIGENS AND NON-SELF-ANTIGENS INTERVENING IN AUTO-IMMUNE CONDITIONS
US7084247B2 (en) 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
US9255131B2 (en) 2004-05-11 2016-02-09 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D.M. GLOVER, "DNA Cloning Volume II A Practical Approach", published February 1986, by IRL PRESS (OXFORD, ENGLAND), pages 191-211, and 213-239. *
G.J. TORTORA et al., "Microbiology an Introduction", published 1989, by BENJAMIN/CUMMINGS (CA), pages 446-447. *
JOURNAL OF CLINICAL INVESTIGATIONS, Volume 74, issued August 1984, J.R. STANLEY et al., "Distinction Between Epidermal Antigens Binding Pemphigus Vulgaris and Pemphigus Foliaceus Autoantibodies", pages 313-320. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 80, issued March 1983, R.A YOUNG et al., "Efficient Isolation of Genes by Using Antibody Probes", pages 1194-1198. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 83, issued October 1986, J.C.R. JONES et al., "A Cell Surface Desmosome-Associated Component: Identification of a Tissue-Specific Cell Adhesion Molecule", pages 7282-7286. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759771A4 (en) * 1995-03-07 1999-12-29 Harvard College IDENTIFICATION OF SELF-ANTIGENS AND NON-SELF-ANTIGENS INTERVENING IN AUTO-IMMUNE CONDITIONS
US7255861B1 (en) 1995-03-07 2007-08-14 President And Fellows Of Harvard College Preparations for inducing immunotolerance and uses therefor
US7084247B2 (en) 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
US9255131B2 (en) 2004-05-11 2016-02-09 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US9533043B2 (en) 2004-05-11 2017-01-03 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US10724103B2 (en) 2004-05-11 2020-07-28 Biontech Ag Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy

Also Published As

Publication number Publication date
AU3178393A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
Amagai et al. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion
KR100496063B1 (en) Novel protein and process for producing the same
Mäntyjärvi et al. Complementary DNA cloning of the predominant allergen of bovine dander: a new member in the lipocalin family
US20080090270A1 (en) Nogo receptor homologues and their use
US20080118951A1 (en) Nogo receptor homologues and their use
JP2012095656A (en) Method for producing novel collectin
CA2098397C (en) Physiologically active substance designated as epimorphin, genes encoding the same, and antibodies thereto
US20030013119A1 (en) Gustducin materials and methods
WO1995017205A1 (en) Recombinant human thymopoietin proteins and uses therefor
EP1146124A2 (en) Gustducin materials and methods
US5599669A (en) Cytokine-induced marker for inflammatory response
JP2001506481A (en) Bradykinin B (1) DNA encoding receptor
EP1527178B1 (en) Class ii cytokine receptors and uses thereof
US20040076992A1 (en) Novel cell adhesion molecule specific to activated leukocyte
WO1993010813A1 (en) Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use
EP1439223A1 (en) Novel class ii cytokine receptor
US5837239A (en) Physiologically active substance designated as epimorphin genes encoding the same and antibodies thereto
KR102731177B1 (en) Biomarker composition for diagnosing massive perivillous fibrin deposition and use thereof
US5599709A (en) Recombinant DNA encoding neuronal α-bungarotoxin-binding proteins
EP1367123A1 (en) Neurotonin and use thereof
EP1130030A1 (en) Human erythroid differentiation related factor
WO2001029079A1 (en) IMMUNO-INTERACTIVE FRAGMENTS OF THE αC SUBUNIT OF INHIBIN
JP2000279171A (en) Canine obesity gene, its gene product, its production method, measuring reagent and measuring method
Piotrowska et al. Cross-reactivity of a monoclonal antibody to the amino terminal region of thyrotropin receptor with the serum protein alpha1-antitrypsin
KR20050083567A (en) Method of evaluating hair growth-promoting activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA